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Abstract
RNAi has great potential in future therapeutics as it has the ability to regulating many
disease-related genes. However, many barriers prevent practical applications. To overcome
the barriers, the specific targeting, efficient delivery system, the validated gene and the potent
siRNA sequence are all vital important. The studies throughout this thesis have been focued
on examining the validation of three RNAi therapies for two different disease models:
allergic contact dermatitis and melanoma. For allergic contact dermatitis, I developed and
tested a novel topical delivery system for siRNAs targeting TNFα (siTNFα) and MyD88
siRNA (siMyD88). While siRNAs applied without the transdermal enhancer are ineffective,
treatment with combined siMyD88 and siTNFα significantly attenuated contact
hypersensitivity (CHS) symptoms in mice, and did so better than treatment with siMyD88 or
siTNFα as single agents. This is the first demonstration of topical gene silencing of TNFα
and MyD88 to treat allergic reactions, highlighting a potential clinical use of RNAi therapy
for skin and allergic diseases. For melanoma, I examined two RNAi therapies using
liposomes attached to mannose and folate ligand, respectively. We developed a novel DC
(dendritic cell)-targeted siRNA delivery system using mannosed liposomes (Man-lipo) with
encapsulated IDO siRNA (Man-lipo-siIDO), which preferentially knocks down IDO in DCs.
Mice treated with Man-lipo-siIDO had a delayed time of onset of implanted murine
melanomas, increased survival time, reduced tumour size, and increased reactivity of T cells
from spleen and lymph nodes against melanoma antigens. This study supports the concept
that Man-lipo-siIDO has potential for development as an immune-targeting therapeutic
anticancer agent. We constructed a liposomal folate receptor-targeting siRNA delivery
system. Compared to controls (non-treatment mice, mice treated with Folate-lipo-siScramble,
or with non-folate-lipo-siBRAF), mice treated with Folate-lipo-siBRAF had reduced tumour
volume, lower tumour weight, and reduced expression of PCNA and vascular networks in
tumour tissue. This study highlights the potential of Folate-lipo-siBRAF for development as
an anticancer therapeutic agent. In conclusion, the therapies for allergic dermatitis that use
topical delivery of siTNFα and siMyD88, for melanoma using the Man-lipo-siIDO or the
Folate-lipo-siBRAF, have the potential to be effective RNAi therapies to treat allergic
dermatitis and melanoma.

Keywords
RNAi therapy, siRNA delivery, Allergic contact dermatitis; siRNA; MyD88; TNF-α,
melanoma, IDO, BRAF, mannose, folate, tumour siRNA delivery, topical siRNA delivery.
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Chapter 1

1

Introduction
1.1

1.1.1

RNAi and siRNA
History of RNAi

Before 1980, RNA was viewed as an inert nucleic acid intermediate for protein
production. This view has changed in the 1980s when Sidney Altman and Thomas Cech
were recognized with a Nobel Prize for their discoveries describing catalytic RNAs [1,
2] . This development inspired many researchers to shift their attention towards these
nucleic acids.
In the late 1980s and early 1990s, many studies demonstrated that expression of sections
of a viral genome in plants protected them from infection by the subsequent virus and
related viruses [3]. It was also found that transgenes led to the silencing of endogenous
genes in a homology-dependent manner and the transgene-mediated gene silencing or
viral protection showed sequence specificity [4, 5]. However, in transgene technology,
researchers observed two unexpected complications. First, most plants with an antisense
transgene did not exhibit suppression of the corresponding endogenous gene [6]. Second,
some of the control lines with the sense construct exhibited coordinate suppression (cosuppression) of the transgene and the homologous endogenous gene [4, 7, 8]. Although
both the antisense and co-suppression mechanism were known to function at the posttranscriptional level, the mechanisms were actually not well understood and so were not
viewed as connected [9].
In 1998, an inspired analysis involving the nematode Caenorhabditis elegans revealed
that injected double-stranded (ds) RNA containing both sense and antisense RNA
preparations could specifically target endogenous mRNA before translation and induce
genetic interference. This phenomenon was named RNA interference (RNAi) by Fire and
colleagues [10-12]. Subsequently, (during 1998 and 2000) it was established in plants
that if dsRNA was produced, suppression of endogenous gene expression was more
efficient than in response to sense or antisense transgenes applied alone. Inverted repeat

2
transgenes were particularly efficient, but simultaneous expression of sense and antisense
RNA was also effective [13, 14].
In 1999, the presumably antisense RNA that guided the degradation of the co-suppressed
RNA was discovered when the size was redirected from >100 nucleotides to up to 25
nucleotides [15]. This second important discovery followed from the search for the
specific determinant of co-suppression in plants. This link between the short RNAs and
RNAi was subsequently confirmed in Drosophila melanogaster. The same work also
confirmed the prediction that the short RNAs guide a ribonuclease complex called RNA
Induced Silencing Complex (RISC) to its target RNA in RNAi [16].
The discovery that short RNAs play a key role in RNAi-mediated suppression of gene
expressions precipitated an avalanche of discoveries that are relevant to the application of
RNAi and co-suppression, as well as understanding of the natural roles of these processes.
For example, short RNAs have been characterized in detail and are now known to exist in
a double-stranded form, with two-nucleotide overhangs at each 3′ end, and are known as
small interference RNA (siRNAs) [17].
During and around 2002, several different proteins were identified as associates with
siRNAs in ribonucleo-proteins [18, 19]. The mechanism for how dsRNA is processed
into siRNAs has also been established. The processing enzyme is known as Dicer, a
member of the RNase III family with dsRNA binding regions and a conserved PIWI–
Argonaute–Zwille (PAZ) domain shared with members of the piwi, argonaute and zwille
enzyme family[20], from which it takes its name. ATP is required at several stages in the
processing of dsRNA and assembly of RISC [21]. In some instances an RNA-dependent
RNA polymerase is also involved in converting a single-stranded RNA into a doublestranded siRNA precursor [22-24].
The discovery of RNA-mediated gene silencing, changed our view of gene regulation and
led to the development of new genetic tools and methods for selective gene silencing, and
have opened a window for developmemt of novel therapeutics against various
diseases[25].
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1.1.2

Mechanism of RNAi action

RNAi is a naturally evolved mechanism in nematodes, insects and plants, as a result of a
developed intrinsic defense against RNA virus and transposons [26]. This characteristic
makes it ideal as the basis for a physiologic approach for both in vitro and in vivo gene
silencing [20, 27]. This mechanism has been described in several eukaryotic organisms
such as Neurospora [28], Drosophila spp [29-31], and mammals [32, 33], including
human cell lines and primary cells [34].
RNAi is induced by endogenous and exogenous small RNAs that include siRNAs and
microRNAs (miRNAs) [32, 35] (Fig 1-1). The process is initiated through cleavage of
dsRNA by a two-subunit RNAse III-family enzyme called Dicer located in the cytoplasm.
This results in smaller, 21-23 nucleotide-long dsRNA fragments termed siRNA
molecules. Each of these siRNA molecules consists of both a sense and an antisense
strand to the homologous RNA target messenger RNA (mRNA) sequence. These siRNA
molecules serve as a trigger for the RISC cellular machinery, composed of associated
proteins and RNA nucleases, which selectively degrade the target complementary mRNA
[20, 36, 37].The endonuclease Argonaute 2 (AGO2) is responsible for the cleavage
mechanism of RISC, and AGO2 is the only member of the Argonaute subfamily of
proteins with observed catalytic activity in mammalian cells [38]. AGO2 is the critical
enzymatic component of RISC: it carries two characteristic domains, named PAZ and
PIWI. RISC activation is thought to initially involve AGO2-mediated cleavage of the
sense or passenger strand of the double-stranded siRNA [39, 40], yielding the singlestranded antisense strand that serves to guide RISC to complementary sequences in target
mRNAs. This guide strand is bound within the catalytic, RNase H-like PIWI domain of
AGO2 at the 5′ end [41] and a PAZ domain that recognizes the siRNA 3′ end [25, 42].
The cleavage of targeted mRNA takes place between bases 10 and 11 relative to the 5′
end of the siRNA guide strand [43], resulting in subsequent degradation of the cleaved
endogenous mRNA [44]. On activation by the siRNA guide strand, RISC can undergo
multiple rounds of mRNA cleavage to mediate a robust post-transcriptional gene
silencing (PTGS) response against the target gene [45].

4
Figure 1-1 RNAi Pathway. Adapted from QIAGEN:
http://www.qiagen.com/products/genes%20and%20pathways/Pathway%20Details.a
spx?pwid=398
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PTGS by mRNA cleavage has been exploited as the method of choice for potential
therapeutic applications of RNAi because of the potency of this catalytic gene-silencing
pathway [46]. In addition to cleavage of perfectly complementary mRNAs, translational
repression and transcript degradation (for imperfectly complementary targets), RNAi
pathways can also direct transcriptional gene silencing (TGS) in the nucleus [47, 48].

1.1.2.1

Maximizing Gene Silencing by RNAi

Maximizing the activity of the effector sequence could be vitally important as it
influences conditions for cellular introduction and/or expression and subsequence
processing [49, 50]. For example, it is been shown that the stable 5’end of antisense
RNA are preferentially incorporated into RISC [49, 51]. Thus, it implies that there are
biases in designing RNAi effectors as better guide strands. There are additional biases in
other positions; for example, high thermodynamic stability is preferred between
nucleotides 5-10 of the guide strand. Furthermore, by comparing multiple sets of active
and inactive siRNA sequences, much experience has been accumulated and is being
applied to the design of optimally active siRNA sequences. Many design tools have been
developed, and have been applied in commercially-available RNAi molecules. To
maximize RNAi activity, it is also important to record and organize the increasing
number of validated sequences developed by the scientific community and commercial
sources. RNAi effectors are designed to correspond to reported active endogenous RNA
sequences. Targeted sequences that are similar to unreported sequences in the genome
(including, for example, single nucleotide polymorphisms or SNPs), might lead to RNAi
effectors being unable to efficiently induce RNAi [52]. However, the influence might be
less than predicted, since RISC is able to tolerate some mismatches, especially those far
from the cleavage site [53, 54]. Despite aberrations in target RNA that could influence
RNAi, they also have the potential to be used to more specifically target mutated
transcripts that relate to disease. This approach has been applied in several contexts, such
as targeting of cancer-specific mutations, targeting of a single-base mutation associated
with the dominant genetic disorder spinocerebellar ataxia, and the silencing of mutant β
globin as an approach to treat sickle cell anemia [54-56]. In addition to potential
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sequence discrepancies, transcript variants of genes targeted for downregulation using
RNAi must also be considered when designing RNAi effectors. With increased
understanding of RNAi, use of more than one effector against target RNA is
recommended when testing the specificity and activity of RNAi-mediated reduction of
each target [57].

1.1.2.2

Off-target effects associated with RNAi

To achieve the best silencing efficiency for RNAi effectors, minimization of off-target
effects is critical. Off-target effects can result from several events, including both
sequence-independent and sequence-dependent processes.
Sequence-independent effects (so-called nonspecific effects) are related to transfection
conditions, inhibition of endogenous miRNA activity, and stimulation of pathways
associated with the immune response. Examples of sequence-independent nonspecific
effects include RNAi machinery saturation [58-60] and immune response against RNAi
effector [61-65]. The studies revealing these effects strongly suggest that the use of the
lowest effective RNAi effectors, and incorporation of negative control RNAi effectors as
comparitors into design of experiments, is essential when planning studies that use RNAi
to explore the function of RNAs.
Sequence dependent effects are associated mainly with associations between RNAi
effector molecules and non-targeted RNAs that are partially complementary to those
RNAi effector molecules: in this case, those non-targeted nucleic acids are silenced by
miRNA-like interactions [65]. Sequence-dependent effects also include receptormediated immune stimulation where certain short nucleotide sequences are recognized by
receptors and are activated by interaction with them [65].
Furthermore, where RNAi is applied in vivo, off-target delivery could induce specific or
non-specific silencing effects in non-targeted organs, tissues or cells. This possibility is
described below (section 1.4, page15).
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1.2
1.2.1

Application of RNAi
In vitro RNAi application

When RNAi is used to target gene expression, gene-specific reagents are introduced into
cells to trigger ‘knockdown’ or reduction of gene function via sequence-specific
degradation and translational interference of mRNA transcripts. This method has truly
revolutionized the field of functional genomics because, unlike other traditional genetic
screening methods, RNAi provides a powerful reverse genetic approach, especially for
organisms with complex genomes a large number of genes (including mammals).
Therefore, RNAi can be used as a powerful tool for genomic studies [66-72]. RNAi
screening provides a powerful reverse-genetic approach for large-scale functional
analysis in cells grown and studied in culture. Cell-based RNAi screening builds upon
established instrumentation and assays, and other methods previously developed for
chemical screening that provide a relatively rapid and accessible platform for genomescale functional studies [66, 68, 69, 71]. A large number of RNAi screens have been
performed in cultured insect (Drosophila) and mammalian cells [66].
Most RNAi-based experiments are designed to achieve sequence-dependent cleavage and
reduction of protein-encoding mRNAs. Although most studies focus on the RNAi
analysis of these targets, any RNA species can be targeted (for example, noncoding RNA
transcripts or viral RNAs). Only a small number of mammalian cell types can tolerate
RNAi induced by large, exogenous dsRNAs (e.g., embryonic stem cells). Thus, in
mammalian systems, it is necessary to select from a variety of RNAi effector molecules
to achieve specific target reduction without unacceptable toxicity. Effector molecules
include siRNA duplexes formed by annealing of two independent RNA strands, or
single-stranded RNA molecules that contain a dsRNA domain, termed short hairpin
RNAs (shRNAs) may be employed. ShRNAs are synthesized from siRNA duplexes that
formed through the annealing of two independent RNA strands, or single-stranded RNA
molecules that contain a dsRNA domain. Both are designed to have full complementarity
with target transcript mRNA without regions of non-complementarity, resulting in target
cleavage and degradation [66].
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SiRNAs used to target RNAs in cultured cells can be generated by annealing singlestranded synthetic oligonucleotides. Most synthetic siRNAs consist of 19 perfectly
matched complementary ribonucleotides with unmatched, single-stranded 3’dinucleotide
overhangs. For ease of synthesis, the synthetic oligonucleotides annealed to generate
siRNAs are often deoxyribonucleotides. SiRNAs can also be generated by a number of
other methods including in vitro transcription, plasmid-based tandem or convergent
expression cassettes, polymerase chain reaction (PCR) [57], but siRNAs generated by
annealing synthetic oligodeoxynucleotids are most common. Transfected siRNAs can
yield a substantial decrease in the steady-state levels of target mRNAs for approximately
24 - 120 h [57].
ShRNAs are designed to mimic miRNA precursors, which are then processed by the
endogenous RNAi machinery and loaded into RISC complexes. A number of different
shRNA expression systems, where shRNA expression vectors are transiently or stably
incorporated into target cells, have been described. Variations in the structure of those
vectors include differences in promoter-terminator combinations, linker sequences,
flanking sequences, duplex length, and regulatory elements that can be used for spatial
and/or temporal specific expression. Additionally, selection markers, used to generate
stable cell lines, and unique sequence elements, used to identify active shRNAs among
larger populations, have been employed. As opposed to siRNAs, the stable expression of
shRNAs allows for a non-transient reduction of targeted mRNAs. Thus, the choice of
RNAi effector (siRNA or shRNA) depends on the situation under investigation [57].
In this study, we focus on the transient siRNA RNAi effector over shRNA in treating
allergic contact dermatitis and melanoma for several reasons: First, allergic contact
dermatitis, a disease induced by the immune systems response to repeated contact with
antigens, does not warrant the long-term silencing of anti-immune-response genes, such
as Tumour necrosis factor alpha (TNF-α) and Myeloid differentiation primary response
gene 88 (MyD88). Consequently, prolonged downregulation of these genes once the
antigen has been removed could increase the risk of future pathogen invasion. Second, in
targeting the host endogenous immune-tolerance gene indoleamine 2, 3-dioxygenase
(IDO) for silencing in melanoma using RNAi, it is understood that this is a normal gene
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that is abnormally expressed in host during the course of the disease. Because IDO is not
normally expressed in adult tissues, it is expected that the normal immune balance will
not be influenced by the silencing effect in the therapy. Third, in targeting the B-RAF in
melanoma, we used the RNAi effector (siRNA) that was fully complementary with the
normal B-RAF mRNA and transiently transfected rather than stably incorporated into
target cells. Thus, rather than long-term silencing, transient silencing of the gene in
tumour tissue was preferred. Here, the transient silencing effects of siRNA offer the
benefit of repeated application of the effectors without long-term effect. Stable silencing,
on the other hand, is mediated by shRNAs that are transported to the cytoplasm via the
miRNA export pathway and processed into siRNAs by Dicer. Direct use of synthetic
siRNA effectors is simpler, does not involve intermediate processer by Dicer, and usually
results in potent gene silencing [73]. Fifth, the method of antisense delivery needs to be
considered. ShRNAs are most efficiently delivered by virus while siRNAs can be
delivered through many of non-viral vectors, such as cationic lipids or polymers [74]. In
our study, siRNAs, but not shRNAs, could be efficiently delivered into cells by a topical
delivery system. We also used a lipid based system to achieve tissue or cell specific
delivery, which performing well in delivering reagents to targeted tissues and cells in
circulation. Moreover, in our lipid based delivery system, we had difficulty in achieving a
shRNA-lipid complex size less than 200 nm in diameter, while 100nm has been described
as the optimum for nano-particles to achieve tissue penetration and cell entry.
Regardless of the RNAi effector used, it is important to include negative control effector
molecules in any RNAi-based experiment. The siRNA controls which are usually
commercially available incorporate sequences with minimal complementarity to any
endogenous transcript.

1.2.2

In vivo RNAi applications

RNAi has great potential to be used in many genetic or acquired diseases. It can be used
to reduce the levels of toxic gain-of-function proteins, trigger cytotoxicity within tumours,
and block viral replication [75, 76]. RNAi can be used to regulate the expression of
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proteins that are not easily accessed by traditional pharmacological approaches, such as
molecules lacking ligand-binding domains or proteins that share high degree of structural
homology. Thus, RNAi based therapeutic approaches are especially appealing to achieve
a high degree of specificity and to target molecules that are considered to be
“undruggable”. In vivo RNAi-mediated knockdown in mouse liver has been reported as a
consequence of high-pressure tail vein injection of both siRNAs and shRNAs [75, 76].
Subsequent in vivo studies have focused on the improved delivery and efficacy of RNAi
effectors. These efforts have used the experience gained through two decades of
developing ribozyme and antisense-based therapeutics and the gene therapy field as a
whole [57, 66].
Several proof-of-principle studies have shown the delivery of fluorophor-labeled siRNA
molecules into various organs [77-79]. Beyond that, the specific in vivo knockdown of
artificially introduced reporter genes like green fluorescent protein (GFP) or luciferase, or
various endogenous target genes, has been described. Due to the body’s natural tendency
to process injected delivery vehicles in the liver, it has become the common target for
antisense therapy, but gene targeting in other organs or in tumour xenografts has been
reported as well. Taken together, these studies provide valuable insights into the delivery
and efficacy of siRNAs for the induction of RNAi [57, 80, 81]. RNAi-based methods are
now a common tool for gene perturbation in mammalian tissue culture cells (mouse, rat,
monkey, and human). Beyond cell culture screens, RNAi is being used in a number of in
vivo studies where the RNAi reagents are delivered topically and directed to specific
tissues or organs, such as the retina, brain, or muscles; used ex vivo (for example in
hematopoietic cells); or delivered as transgenes [67, 82].s

1.3

RNAi therapies

RNAi has great potential in future therapeutics as it has the potential to regulate diseaserelated genes. In essence, all any human disease caused by inappropriately increased
activity of one or more genes could, in theory be regulated by RNAi-based therapies [73].
The numbers of RNAi-based preclinical and clinical trials have grown over the past
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several years and have included studies in retinal degeneration, dominant-negative
inherited brain and skin diseases, viral infections, respiratory disorders, cancer and
metabolic diseases [83]. To date, RNAi therapies in clinical trials have targeted
approximately 14 different diseases [83]. Numerous siRNA therapies are at preclinical
stage. The delivery methods for siRNA drugs are continually improved to maximize the
specificity of siRNA delivery while minimizing toxicity and degradation effects that
compromise drug efficacy [74]. Strategies exist that use synthetic materials or natural
carriers (viruses and bacteria), and the preferred method typically depends on the
application, the required duration of the therapeutic, and the targeted tissue.
Three clinical trials have used ex vivo delivery of the siRNA/shRNA therapeutics, in
which cells were collected from patients, treated with siRNAs/shRNAs and reimplanted/re-infused back into the patient [81]. This procedure is known as autologous
cell therapy. One of the three clinical trials involves use of an anti-tumour bifunctional
siRNA (bi-siRNA) for treatment of metastatic melanoma. A phase I clinical trial at Duke
University (Durham, North Carolina, USA) is focusing on an siRNA drug to treat
metastatic melanoma, a form of cancer that originates in melanocytes. Patients in this
study are treated with autologous DCs (dendritic cells) transfected with siRNA in
combination with mRNAs that encode for various tumour antigens. The purpose of this
therapy is to install an anti-melanoma immune response by alteration of proteasomemediated processing in combination with increased immune recognition of melanomaassociated antigens [84, 85]. The siRNA-induced knockdown of the proteasome is
thought to enhance the presentation of melanoma antigen by the DCs with the aim of
provoking a strong immune response against the melanoma cells in these patients. Ideally,
cancer cells will be killed through the actions of the patient’s own immune system. Part
of this thesis (on pages 104 to 133) describes an APC-targeting siRNA therapy for
treatment of melanoma. In this approach, I used the strategy of silencing IDO expression
in antigen presenting cells (APCs) in order to reinstall the capacity of endogenous
immune cells to recognize tumour antigens and activate anti-tumour immune response
against cancer cells.
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To date, there are nine siRNA therapies at various stages of clinical testing, all involving
intravenous injection as the route of administration. Among these are five that use a
cationic liposome delivery technology, four that use the stable nucleic acid lipid particle
(SNALP) carrier developed by Tekmira, and one that uses an siRNA-lipoplex known as
AtuPLEXTM [86-90]. A Phase I clinical test that is currently being conducted by Silence
Therapeutics (London, UK) that employs an siRNA lipoplex that targets proteins kinase
N3 (PKN3) in advanced solid cancers [91, 92]. In two studies described in this thesis (on
pages 104 to 133 and 140 to 170), we also employ cationic liposomes as the delivery
system and use siRNA lipoplexes as a potential therapy for treatment of melanoma. In
our studies, we tested the use of targeting ligands to guide siRNA lipoplexes to specific
cell types and achieve specific gene downregulation preferentially in target cells that
express molecules on their surfaces capable of binding those ligands.
Systemic delivery methods that often require injection of the siRNA into the bloodstream
are being tested for siRNA delivery to the kidney, liver, and some solid tumours [90].
Similarly, RNAi drug candidates can be injected directly into the desired tissue or tumour
to release the drug with the degradation of a biodegradable carrier. Tissues such as the
eye, lung and skin are suitable for topical delivery siRNA [93].

1.3.1

The potential of RNAi therapy for cancer

Cancer is a disease characterized by self-sufficiency in growth signalling, insensitivity to
growth-inhibitory signals, evasion of programmed cell death (apoptosis), limitless
replicative potential, sustained angiogenesis and tissue invasion [94-98]. Malignancy is a
result of long-term accumulation of genetic and epigenetic alterations. While various
cancers and/or different patients commonly share some of those alterations, heterogeneity
is usually unique in different tumours and in different patients. As a result, tumour
molecular profiles differ from patient to patient and personalized therapy is needed.
RNAi has the advantages of specificity, adaptability and breadth of targeting capability,
thus giving it great potential to serve as a method for personalized gene therapy for
cancer. Antisense therapy in particular has advantages in knocking down RNA targets
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that are up-regulated during, and/or are causally related to, cancer progression. In
addition, upregulated proteins that mediate malignant characteristics and are, for a variety
of reasons, difficult to target with small molecules or antibodies (e.g., poor affinity for
target, cross-reactivity with other essential molecules in normal cells leading to
unacceptable toxicity) may be good choices for suppression using RNAi targeting the
mRNAs that encode them.

1.3.2

Challenges in tumour siRNA delivery

There are many challenges to applying siRNA in cancer therapy, including the major
issue of selective delivery of intact siRNA to target cells and cellular compartments. The
common barriers for siRNA delivery to both non-solid cancers (e.g., leukemia) and solid
tumours are degradation in the blood stream and extracellular fluids (including both the
stability of the delivery system and the siRNA itself), surface opsonization and
subsequent entrapment by the mononuclear phagocytic system and reticuloendothelial
system, and rapid renal clearance [99, 100]. For solid tumours, which make up 85% of
human cancers, the delivery of siRNA from injection site to tumour involves transport by
the circulation system to tumours, extravasation from tumour vasculature, and transport
in tumour interstitium. In this process, diffusion and convection is more important than
transcytosis [101]. There are barriers in each of the processes.
Tumours have vasculature that is poorly organized, tortuous, defective and displays
location-dependent heterogeneity [102]. Compared to normal tissue, tumours have lower
blood flow, higher flow resistance and, as a result, lower exposure to siRNA injected
intravenously. On the other hand, tumour blood vessels have discontinuous endothelium
which makes them leaky and permeable to larger size molecules (100–780 nm). This
property facilitates diffusion of larger siRNA-containing nanoparticles (e.g., 100 nm
diameter or more) from blood vessels into the interstitial space to allow passive tumour
targeting [102].
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In solid tumours, the lymphatic system is impaired, preventing particulates and interstitial
fluid from rejoining circulating blood. This enhances retention of macromolecules and
siRNA-containing nanoparticles in tumour interstitium which, combined with the effect
of leaky blood vessels in tumours, results in enhanced permeability and retention (EPR)
of administered therapeutic nucleic acids in tumours[103]. The absence of lymphatic
drainage also increases the interstitial fluid pressure (IFP) which, in turn, reduces the
hydraulic conductivity and fluid flow, and results in reduced of convective extravasation
and interstitial transport.
Interstitial transportation of siRNA-containing nanoparticles into tumour cells occurs
mainly through convection, which depends on hydraulic conductivity and pressure
gradient. The structure of the extracellular matrix (ECM) or stroma creates barriers for
siRNA transport. Proteins found in the ECM such as collagens, glycosaminoglycans,
preoteoglycans, fibrous proteins and glycoproteins, pose barriers to siRNA-containing
nanoparticle delivery by presenting physical obstacles or by binding to the complex [102].

1.4

Introduction to siRNA delivery

Over the past two decades, altering or manipulating gene expression has shown great
potential in a wide variety of diseases. Since the idea of gene delivery illustrates
treatment of disorders at the genetic level, the principal of gene delivery has been well
discussed and established [104-106]. Classical gene delivery mainly includes two
systems: viral vectors and non-viral delivery systems. Viral delivery systems are far more
efficient than other gene delivery systems. However, many obstacles such as innate
immunity issues, and the potential of oncogenicity and mutation insertion risk limits its
wide application [104]. Non-viral delivery systems are considered to be safer and
immunologically protective [104].
The choice of delivery system also depends on the differences of RNAi effectors, which
includes long dsRNAs, shRNA and siRNA.
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Long dsRNAs (200-500 nucleotides) can be injected into animals or (in most cases) into
blastocysts to achieve widespread stable incorporation and expression in multiple cells
and tissues, delivered by bacteria, expressed as transgenes, or delivered into cultured cells
by transfection or bathing cells in dsRNA-containing medium. In endoribonucleaseprepared siRNA methods, long dsRNA are used to produce a pool of small siRNAs that
are then transfected into cells [107]. However, long dsRNAs are usually not used in
mammalian systems since they trigger an unwanted interferon response that masks genespecific effects [67].
ShRNAs are usually expressed from plasmids or virus based expression vectors. The first
studies applying shRNAs in vivo used plasmid DNA [108]; Most subsequent studies,
however, have focused on the use of viral vectors. The choice of viral delivery system
usually depends on the cell type under investigation and on the need for short- or longterm shRNA expression. Until now, most shRNA-based studies have employed the
standard viral vector expression systems used in traditional gene therapy [86].
siRNAs play an entirely different role in the transcription and expression process for
short-term non-viral nucleic acid delivery [109]. siRNAs are potent and specific
inhibitors of gene expression and are being used as a new technology for drug target
validation, study of functional genomics, design of transgenes and as promising
therapeutic agents for diseases with a genetic etiology [110].
In vitro, siRNAs are usually transfected into cultured mammalian cells by standard
physico-chemical methods, such as methods based on cationic lipids, cationic polymers
or electroporation. Different cell systems might have different efficacious transfection
methods [111].
In vivo delivery of siRNA has many challenges. First, naked siRNAs are not stable in
serum. They are either easily degraded by RNAase or easily removed by renal clearance,
which results it a short half-life in serum. Therefore, some investigators tried to
chemically modify the sugars, the backbone or the base of oligoribonucleotides to
stabilize the siRNA molecule without impairing capacity to specifically and efficiently
knock down the target [112, 113]. However, the cell membrane is hydrophobic and
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negatively charged, which creates a barrier by repelling the hydrophilic and negatively
charged polymers. Additionally, siRNAs only transiently silence the intended gene
product when they enter the cell since the concentration decreases with each cell division
[46]. Nanoparticle carriers have the ability to prevent siRNAs from intravascular
degradation and to deliver them into cells safely and efficiently and with lowered risk of
degradation and/or interaction with non-target molecules en route to target cells and
tissues. However, in the bloodstream, nanoparticles will encounter many non-target
molecules and non-target cells, including monocytes, leukocytes, platelets and dendritic
cells. Nanoparticle uptake by immune cells can lead to subsequent (and potentially
undesirable) immune responses. Moreover, the physical and chemical properties of the
nanoparticle surface, such as size and surface charge, may also lead to haemolysis,
thrombogenicity and complement activation, resulting in altered biodistribution and
potential toxicity [114].
Second, to achieve effective RNAi application in vivo, barriers to entry into tissues and
targeting of intracellular compartments must to be overcome. Nanoparticles for siRNA
are ranged from 1nm to 1000 nm in diameter. However, for safe and effective delivery of
RNAi to targeted mRNAs, it is now clear that nanoparticles >100 nm in diameter are
likely to be trapped by cells of the reticuloendothelial system (RES) in the liver, spleen,
lung, and bone marrow when intravenously injected in vivo, leading to RNAi effector
molecules by activated monocytes and macrophages. Thus, nanoparticles of around 100
nm in diameter are thought to be optimal for avoiding RES clearance [115].
Third, cell entrance and endosomal escape are crucial issues for effective siRNA delivery.
Many nanoparticles enter cells by endocytosis [116]. As soon as the nanoparticle is
endocytosed by cells, it begins travel in early endosomal vesicles. The early endosome
will then fuse with sorting endosomes, which transfer their contents to late endosomes.
The late endosomes maintain a low pH through the activity of membrane-bound protonpump ATPases. Late endosomes will relocate to lysosomes, which are acidic (~pH4.5)
and contain nucleases that degrade RNA [117]. Thus, if the nanoparticle is not able to
escape from the endosome, siRNAs will not be released into the cell cytoplasm and
function as RNAi effectors. Mechanistic approaches designed to promote endosome
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escape involve the use of fusogenic lipids, fusogenic peptides, photosensitive molecules,
pH-sensitive lipoplexes, and pH-sensitive polyplexes. Fusogenic lipids promote
endosomal release by increasing the interactions between liposomal and endosomal
membranes. pH-sensitive materials use proton “sponge” effects, in which the delivery
material induces an influx of chloride ions and subsequent osmosis, resulting in
endosomal rupture and the release of endosomal contents [117].
Fourth, the intracellular factors have drawn the majority of research efforts; less
commonly studied extracellular factors in the tumour microenvironment could be more
important. For example, in the targeted delivery of cancer cells, nanoparticle must
exravasate and move through the ECM to reach the cancer cells. This complex tumour
microenvironment poses a challenge for accumulating therapeutic drug concentrations in
target cells [118]. The biological and physical properties of the ECM could result in the
unpackaging of nanoparticles and the release of their contents prior to delivery to target
cells [119]. These dynamic factors in vivo stress a limitation of in vitro testing that are
inherently static conditions that do not reflect dynamic forces in vivo and, therefore, may
inaccurately predict in vivo effectiveness. To minimize this disparity three dimensional
models could be useful in imitating the ECM barriers for nanoparticles delivery [120].
The immune system is also an important extracellular barrier. Particles deviating from an
overall neutral electrical charge (i.e. cationic or anionic) are more easily phagocytosed
by macrophages like Kupffer cells in liver and dendritic cells in lymph nodes than those
in neutral nanoparticles [114]. Besides macrophages, neutrophils can also function as
extracellular traps for nanoparticles [115, 121, 122].

1.4.1
1.4.1.1

Topical siRNA delivery
Skin structure

Skin has a surface area that approximately spans over 2 m2 in the average adult. It shields
the body from the environment and protects the body from toxic chemicals, ultraviolet
radiation, microorganisms, and mechanical trauma. It is of vital importance in preventing
water and electrolyte loss. Skin is also an important organ for excretion of certain
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substances, immunological sensing, and in regulating body temperature by direct
radiation and secretion of water [123, 124] .
There are three major layers of skin: epidermis, dermis, and underlying subcutaneous
tissue (Figure 1-2). The barrier function of skin relies mainly on the epidermis. The
epidermis is composed of keratinocytes, including the stratum basale (basal cell layer),
stratum spinosum, stratum granulosum, and stratum corneum (from body to surface, in
that order). Immediately under the epidermis is the basal lamina, which supports the
epidermis. The dermis contains capillary and lymphatic vessels, and skin appendages
such as nerve endings, hair follicles, sebaceous glands, and sweat glands. Hair follicles
and sweat ducts open directly into the environment at the skin surface and provide the socalled appendageal route of skin permeation, which is very important for topical drug
delivery. Below the dermis is the subcutaneous layer which provides insulation,
protective padding, and energy storage [125, 126].

1.4.1.2

Advantages and challenges of topical delivery of siRNA

Increased understanding of the components of signaling pathways, coupled with
generation of small molecules and antibodies capable of interacting with those
components, has profoundly influenced treatment of inflammatory diseases, cancers,
genetic disorders, and diseases in skin [127-129]. However, most protein-based
therapeutics are costly, have limited targeting ability, and can lead to systemic toxicity
when applied systemically [130, 131]. Topical delivery of siRNA is particular attractive
for treatment of skin disorders, because proteins larger than a few hundred daltons are not
easily delivered into skin, and high concentrations of proteins are necessary for cutaneous
effect [132]. SiRNA has great potential for treatment of skin disease by specifically
inhibiting expression of one or several proteins. Topical delivery of siRNA allows
preferential, direct targeting of skin cells [94]. Cutaneous delivery of siRNA is locally
restricted to the affected skin area, the systemic dose of topically applied siRNA is
significantly less than for intravenous administration, and topical delivery can lead to
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Figure 1-2 Skin structure.
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high local cutaneous dose (assuming good skin penetration). Generally speaking,
molecules less than 500 Da have high penetrating capacity [133], As result, systemic
toxicity is reduced [134]. Moreover, the region to which siRNA is applied can be visually
monitored or easily biopsied if monitoring of therapeutic effects and/or pathological
analysis is required. Also, topically siRNA delivery is user-friendly. Three siRNA
topically-delivered drugs are undergoing clinical trial, including siRNA eye drops for the
treatment of ocular hypertension and glaucoma (from Sylentis, Inc.), an inhaled siRNA
drug for asthma (from ZaBeCor, Inc.), and an siRNA drug for respiratory syncytial virus
(RSV, from Alnylam, Inc.)ccz delivered to human patients by nebulizer and nasal spray
[126]. However, the cutaneous delivery of siRNA still faces many obstacles. The
penetration of oligonucleotides through the epidermis barrier becomes the predominant
major technical challenge in cutaneous delivery of siRNA [135].
In vivo delivery of siRNA is challenging, since siRNA itself has difficulty being absorbed
by skin and it is relatively unstable and subject to degradation prior to interaction with
target RNA [136]. Moreover, siRNA is negatively charged and relatively large: this leads
to repulsion by cell membrane (also negatively charged) and difficulty in being taken up
by cells through pores in plasma membranes. Regardless of that, keratinocytes have the
ability to take up unmodified DNA or siRNA in a mouse skin model [123, 125, 137-139].
This is important in that it suggests that cutaneous gene therapy is feasible. However,
keratinocyte uptake of nucleic acids without modification (or encapsulation in delivery
vehicle) requires intradermal injection, which is not user-friendly and is painful when
repeated injection is necessary. Moreover, injection can applied to only a small area of
skin for each injection site, which makes it limited for application to larger skin areas or
whole body skin diseases. Thus, penetration-enhancing techniques are needed for
cutaneous topical siRNA delivery.
Stratum corneum (SC) in epidermis is the major barrier to cutaneous siRNA delivery.
The SC is composed of terminally differentiated nonnucleated keratinocytes (also called
corneocytes). These cells run perpendicular to the skin surface and are packed in tight
columns. The cellular matrix between corneocytes is composed of hydrophobic non-polar
lipids. Those lipids are assembled into lamellar stacks to form a very densely packed
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structure [126], that is resistant to permeation by topically-applied siRNA. Moreover, the
dense network of polysaccharides and fibrous proteins also creates a barrier for siRNA
penetration. Since the basal membrane is an electron-dense adhesion structure, even
topically-delivered siRNA that passes successfully through the barrier of the stratum
corneum has difficulty in entering cells and reaching reaching target RNA [127].
In my study, I generated a chemical siRNA transdermal enhancer composed of three
chemical reagents selected to assist in moving siRNA through multiple barriers in skin
and skin cells to reach target mRNA. We applied the new cutaneous delivery reagent and
siRNA complex to treatment of allergic contact dermatitis (ACD).

1.4.2

Lipid based siRNA delivery

Currently, most in vivo studies use synthetic lipid-based siRNA carriers with or without
modifications to the carriers themselves. The beneficial properties of liposomes as drug
delivery vectors were first recognized in the 1970s, spurring an increase in
biopharmaceutical research on this area that has steadily increased since then [140-142].
Liposomes are spherical soft matter particles consisting of one or more bilayer
membrane(s), and are most commonly composed of phospholipids encapsulating a
volume of aqueous medium. Liposomes boast many advantages as a drug carrier such as
good biocompatibility, biodegradability, low toxicity and structural variability [143].
Cationic liposomes in particular serve as good candidates for the delivery of siRNA. First,
properly designed cationic liposomes have demonstrated potent transfection efficiencies
both in vitro and in vivo [144]. Cationic liposomes can tightly compact and encapsulate
siRNA through electrostatic interactions, thus protecting the siRNA from circulation
dynamics and nuclease degradation while traveling in the vasculature [145, 146]. Second,
the size of cationic liposomes can be manipulated through extrusion [147], preventing
excretion in the urine when too small or blocking of the microcirculation when too large.
Particle size is also of vital importance in optimizing ability to overcome the tissue
barrier, transfecting cells efficiently, and regulating surface properties. Third, the
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structural variability of liposomes allows a variety of modifications, such as conjugation
of ligands or polymers onto the surface for targeting delivery, and addition of other
modulator molecules to the interior compartment of liposomes to improve transfection
[144]. The cationic surface of the liposome helps to shield the electrostatic repulsion
between the cell membrane and naked nucleic acid, aiding in uptake. The cationic
liposome is at least 1000 fold more efficient in delivering encapsulated nucleic acids than
delivery of naked nucleic acids [148].

1.4.2.1

Mannose liposome delivery

Mannose receptors are highly expressed in cells of the immune system (i.e., macrophages
and DCs, especially in professional APCs [149-153]. Transmembrane mannose receptors
mediate endocytosis, function as antigen capture receptors and are involved in antigen
capture and presentation [154-156]. The preferential expression of mannose receptors in
the cells of the immune system makes it a promising target for various therapies,
including chemotherapeutic treatments targeting macrophages, vaccines against DCs
[157], and gene delivery to APCs. Mannosylation has been successfully applied to
vaccination and, in fact, several constructs are currently undergoing clinical trials [158].
Mannosylated particulates are formed by the association of the mannose derivative to a
carrier (liposome, nanoparticle, etc.). The mannose derivative acts as a targeting agent
whereas the particulate or carrier acts as a reservoir for the therapeutic agent. Their
particulate nature allows these particles to be engulfed by phagocytic APCs and
mannosylation will further improve their phagocytosis mediated by specific receptors.
Compared to other carrier delivery systems, liposomes offer multiple advantages for drug
delivery, including their biocompatibility, biodegradability and safety. Mannosylated
liposomes are considered to be promising non-live vectors for targeted delivery purposes.
In fact, mannosed liposomes have been successfully applied in APCs targeting DNA
vaccine against cancer [159] and protein vaccine delivery against N. meningitides [160].
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1.4.2.2

Folate liposome delivery

Folic acid is a water-soluble B vitamin essential for the de novo synthesis of DNA and
one carbon transfer reactions in cells [161]. In vivo, folate receptor (FR) has high affinity
for folate.
FRs, also known as folate-binding proteins (FBPs), are N-glycosylated proteins with high
binding affinity to folate. FRs include at least four isoforms: , ,  / γ ′and δ. The
affinities of folic acid for the FRs are: FR-α , Kd~ 0.1 nM [162]; FR-β , Kd ~1 nM [163];
and FR-γ , Kd ~ 0.4 nM [164]. Functional FR expression is low or absent in most normal
tissues, with FR-α expression limited to the luminal surface of certain epithelial cells and
inaccessible to blood circulation [165]. In contrast, many malignant cancers such as those
arising in brain, kidney, lung, and breast and, in particular, in epithelial carcinomas such
as ovarian cancers, consistently and uniformly express high levels of FR-, which is
accessible to circulating blood [161, 166].
FR-β is a differentiation marker in the myelomonocytic lineage during neutrophil
maturation [167] and is amplified in activated monocytes and macrophages [168]. FR-β
is functionally expressed in certain cancers, such as chronic myelogenous leukemia
(CML) and in 70% of acute myelogenous leukemias (AML) [111, 169].
The soluble FR-/γ ′ is expressed mainly at low levels in certain haematopoietic cells,
and has a relatively insignificant role in FR-targeted drug delivery.
FR-δ is expressed on regulatory T cells and has recently been discussed as a potential
therapeutic target [170].
The frequent overexpression within tumours and highly restricted distribution in normal
tissues suggest that both FR- and - can potentially be exploited as a tumour-specific
cell surface marker that can be used in the targeted delivery of cancer therapeutics [161,
171].
Folate-based targeting systems have already been successfully applied as a therapeutic
agents and imaging agents [172, 173]. Folate liposomes have good biocompatibility,
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biodegradability, and safety. Further, liposomes are able to accumulate within tumour
tissue due to the passive accumulation of colloidal macromolecules of approximately 40
kDa and above, which contributes to the EPR [174]. The accumulation of liposome in
tumour tissue could be further improved through the use of receptor targeting moieties
(i.e., folate) that are either conjugated to the surface of liposomes after encapsulation or
siRNA, or are attached to lipids that become incorporated within the liposomal bilayer
during liposome assembly [175].
Conjugation of folate to a lipid-PEG linker through theγ-carboxyl [171, 176] of folate
serves to both anchor the folate molecule to liposomes and maintain its affinity to the FR.
Therefore, liposomes that included folate-conjugated lipids are considered to be
promising non-live vectors for targeted delivery of therapeutic molecules to tumours.
Two different disease models (ACD and melanoma) were used to examine the three
targeted RNAi-based therapies described in this thesis.

1.5

Introduction to allergic contact dermatitis

Contact dermatitis is an eczematous skin reaction caused by direct and usually repeated
exposure to harmful objects or chemicals. It is one of the most common skin diseases and
may vary from slight hyperkeratosis and small fissures to extensive redness, swelling and
scaling [177]. There are three types of contact dermatitis: ACD; irritant contact dermatitis,
and photo-contact dermatitis. ACD is known the most prevalent form of immuno-toxicity
in humans.
ACD is the consequence of an undesired immune reaction to hapten contacting the skin.
It is a type IV delayed hypersensitivity [178, 179]. Its initiation needs the development of
the effector T cell response against the hapten, which results in the skin inflammation.
There are two phases during this process: the sensitization phase and the elicitation phase.
The sensitization phase begins with contact between skin and hapten and leads to
generation of hapten-specific T cells in lymph node (LN). Those hapten-specific T cells
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then return to skin. Haptens induce sensitization through two distinct properties: intrinsic
pro-inflammatory properties, and by binding to amino acid residues in self-proteins to
generate new antigenic determinants in skin [180]. When haptens induce sensitization
through their pro-inflammatory properties, they activate innate immune activity in skin
tissue and deliver signals which induce the migration and maturation of cutaneous DCs.
When haptens induce sensitization by binding to amino acid residues to modify self
proteins, the haptens or haptenated proteins are loaded into cutaneous DCs and are
expressed as haptenated peptides in the groove of major histocompatibility complex class
I (MHC I) and class II molecules of those cells. Those DCs will migrate from the skin to
regional lymph nodes (LNs) where they are capable of priming CD8+ and CD4+T cells
for recognition of those antigens. T cells will then proliferate and migrate out of LNs and
circulate between the lymphoid organs and the skin. The sensitization step lasts 10 to 15
days in man, and 5 to 7 days in the mouse.
In the elicitation phase, the challenge with the same hapten in the sensitized individuals
leads in the apparition of ACD. When haptens diffuse into the skin and are taken up by
skin cells that express MHC I and II/haptenated peptide complexes, hapten-specific T
cells are then activated in the dermis and epidermis and trigger the inflammatory process
responsible for the cutaneous lesions. Understanding of ACD derives from experiments
undertaken in animal contact hypersensitivity (CHS) model. CD8+ cytotoxic T
lymphocytes are the main effector cells of CHS and they are recruited early after
challenge. The elicitation phase of CHS takes 72 hours in man, and 24 to 48 hours in
mouse. The inflammatory reaction persists for only a few days and then rapidly decreases
following down regulatory events [178].

1.5.1

The role of TNFα and MyD88 in contact dermatities

TNFα is a cytokine known to be involved in systemic inflammation. The primary role of
TNFα is in the regulation of immune cells [181]. It activates neutrophils, up-regulates
expression of the endothelial adhesion molecules, increases capillary permeability and
has a direct cellular toxic effect. In the CHS model, the release of TNFα can activate
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local endothelial cells and facilitate T cell recruitment [181, 182]. Among the mediators
of inflammation, TNFα is one of the most important factors and plays a major role in the
elicitation of CHS [183]. TNFα that released by mast cells and platelets is important in
initial recruitment of T cells [184, 185].
The MyD88 is critical for signaling from all Toll like receptors (TLRs) except TLR3
[186], and is expressed in a variety of human and murine tissue albeit at varying levels
[187]. Its involvement in the Toll/interleukin-1 receptor (TIR) signaling pathway, results
in NF-кB activation, cytokine secretion and and inflammation. MyD88-deficient mice are
unable to mount a CHS response [188].
Most information about ACD has been acquired using a mouse model of induced CHS
[183]. In this study, we use this model and 1-fluoro-2, 4-dinitrobenzene (DNFB)-induced
CHS in mice, which is well-established as a model inducer of CHS to model ACD [189].

1.6

Introduction to melanoma

Melanoma is the sixth most common cancer and the human malignancy with the highest
recent rise in incidence (a rise that continues) [86]. Melanomas can arise at any
anatomical site occupied by monocytes. However, cutaneous melanoma, which develops
from epidermal skin melanocytes, represents the most common site of origination. In this
study, I focus on cutaneous melanoma. Cutaneous melanoma is the deadliest form of skin
cancer and it is arguably one of the most aggressive malignancies overall. Classically, the
pathological workup for melanoma includes description of the growth pattern and
measurement of vertical thickness (also called Breslow) [131]. Superficial spreading
(nodular, acral lentiginous, lentigo maligna, lentiginous and desmoplastic) are all
included in histological growth patterns. Although prognosis depends on lots of data,
such as ulceration and penetration through cutaneous layers or mitotic rate, Breslow
thickness is the critical prognostic parameter.
In 2009, the American Joint Committee on Cancer (AJCC) updated melanoma TNM
classification categories [132] (Table 1-1, 1-2) . Mitotic rate and ulceration become
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Table 1-1TNM classification AJCC 2009
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TNM classification AJCC 2009 [132]
T

Thickness

Ulceration, Mitotic rate

T1

Up to 1 mm

a. No ulceration and <1 mitosis/mm2
b. Ulceration or >1 mitosis/mm2

T2

01 - 2 mm

a. No ulceration
b. Ulceration

T3

1-4 mm

a. No ulceration
b. Ulceration

T4

>4 mm

a. No ulceration
b. Ulceration

N

Number of nodes

Tumour burden

N1

1

a. Micrometastasis
b. Macrometastasis

N2

2-3

a. Micrometastasis

N3

>3 or in transit satellites with metastatic
nodes

b. Macrometastasis

M
M1a Distant soft tissues, normal LDH
M1b Lung, normal LDH
M1c Other viscera or elevated LDH

c. In transit satellites but no distant
nodes
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Table 1-2AJCC 2009 staging classification
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AJCC 2009 staging classification [132]
IA

T1a

IB

T1b

IIA

T2bT3a

IIB

T3bT4a

IIC

T4b

IIIA

T1a-T4a N1a-N2a

IIIB

T1b-T4b N1a-N2a

N0M0

N+M0

T1a-T4a N1b-N2b-N2c
IIIC

T1b-T4b N1b-N2b-N2c
Any N3

IV

Any M1

M1
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important with tumour thickness in patients with localized melanoma. The N category
depends on the number of positive lymph nodes, tumour burden, and ulceration in
patients with metastatic lymph nodes. Among patients with localized disease, it is
important to define a subgroup of patients with a greater rate of relapse. This population
receives adjuvant therapy [131].
Patients with stage IIB, IIC or III disease, such as those with ulcerated tumours with
Breslow thickness 2-4 mm, tumours with Breslow thickness >4mm, or tumours with
positive lymph nodes are considered to be at high risk [131]. Among those at high risk,
differences in prognosis can be marked. For example, while patients with stage IIIA
disease have a ten-year overall survival rate of over 70%, stage IIIB and IIIC have only
40% and 25% ten year survival rates, respectively. Stage IV survival rate depends on
tumour burden and the location of metastases. While average survival in this stage is 6-7
months, less than 10% of the patients survive longer than one year [131]. There is
promise that this survival rate will be increased by application of inhibitors of v-Raf
murine sarcoma viral oncogene homolog B1 (B-RAF) in the future [132]. For several
decades progress in melanoma treatment has been slow. However, new staging
classification, insights into the patterns of relapse at early stage, better understanding of
the molecular biology underlying the malignant characteristics of melanoma, and
development of new drugs for treatment of advanced diseases, have all increased
progress. Effort has now focused on identification of altered gene pathways (knowledge
of which is known to be helpful in diagnosis) and the development of new therapeutics
[131]. The identification of mutant B-RAF as a major driver of melanoma progression
highlighted targeting of B-RAF as a therapeutic opportunity in treatment of melanoma
[131].
Several years following discovery of B-RAF mutations in melanoma, the first selective
inhibitor (vemurafenib) entered clinical trials. However, although tumour regression
during and after the early course of the therapy was observed, resistance to therapy
emerged during subsequent treatments. The response duration ranged from 2 to >18
months. Current research focuses on mechanisms underlying resistance to B-RAF [190].
Because siRNA therapy targets a major mechanism underlying resistance to targeted
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agents (i.e., target overexpression), it’s use may be desirable to help avoid resistance that
can develop following treatment with small molecule inhibitors that target specific
proteins without reducing mRNAs available to mediate increased synthesis of additional
target molecules. Moreover, targeting mRNA sequences has increased potential to
enhance target specificity and reduce off-target effects.
Melanoma is characterized as one of the most immunogenic tumours due to the presence
of tumour infiltrating lymphocytes in resected melanoma, occasional spontaneous
regressions, and clinical responses to immune stimulation. The immunogenicity of
melanoma has led investigators to study novel immune strategies to overcome tumour
immune evasion [191]. One mechanism relates to indoleamine 2, 3-dioxygenase (IDO), a
molecular express on APCs could block T cell activation and induce T cell apoptosis,
generating more regulatory T cells and thereby create a tolerance immune environment
for tumour progress. In 2007, dextro-1-methyltryptophan (D-1MT), a classical IDO
inhibitor, entered clinical trials. It is able to influence complex culture systems, in which
many proteins take place in immunoregulatory role. However, it observed that D-1MT
did not inhibit purified IDO [130]. A paradox has emerged that the immunoregulatory
role of D-1MT needs IDO expression to function whereas its ability of inhibiting purified
IDO is weak. The mechanism of why D-1MT needs IDO expression in mice to function
and its effect in clinical trials still need to be further studied. As the inhibitory activity for
both of the isomers (D-1MT and L-1MT) of 1MT are weak, it is questionable whether
they will ever be useful in the clinic as IDO inhibitors. Gene silencing by therapeutic
nucleic acids, particularly siRNA, is a promising way of specifically inhibiting the
expression of a protein with potential in cancer therapy [192].
Two difference approaches, in which two molecules that have great potential of being
used as therapeutic molecular in the future have been targeted in our study: IDO and BRAF.
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1.6.1

Introduction to IDO

Cutaneous melanoma arises from the largest organ with immune function, the skin.
Neoplastic cells can bypass immune surveillance by influencing and inhibiting immune
cell function at virtually all stages of tumour development, including initiation,
promotion/progression, and tumour invasion and metastases. IDO expression in DCs has
been identified as a property of those cells that decreases DC function and contributes to
immune tolerance of tumours. IDO is the first and rate-limiting enzyme of tryptophan
catabolism in the kynurenine pathway (Figure 1-3), thus depleting tryptophan and
reducing T cell growth and activity [193].

1.6.1.1

Tryptophan and kynurenine pathway

L-Tryptophan (L-Trp) is an essential metabolite in mammals and the least abundant of all
essential amino acids (Figure 1-3). It must be metabolized through several strictly
controlled pathways to form biologically active compounds [194]. These compounds
include: aminergic neurotransmitter serotonin (5-hydroxytryptamine, 5-HT),
neurohormone melatonin, several neuroactive metabolites of melatonin, products of the
kynurenine (KYN) pathway, and tryptamine [195]. Among the several metabolic
pathways for tryptophan, the kynurenine pathway is the main route of non-protein
metabolism (Figure 1-3). Under normal circumstances, protein catabolism is balanced by
protein synthesis so that the protein-related pool of tryptophan remains fairly constant.
While the protein related pool of L-Trp is constantly balanced, approximately 99% of
dietary intake L-Trp is processed by the kynurenine pathway of catabolism [196] making
its importance vital in L-Trp metabolism.
In the kynurenine pathway, IDO and tryptophan 2,3-dioxygenase (TDO) are cytosolic
heme dioxygenases that catalyze the oxidative cleavage of the C2-C3 bond of the indolic
ring of L-Trp. This reaction is the first and rate-limiting step of the kynurenine pathway
of tryptophan catabolism [197-199].
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Figure 1-3 Schematic representation of kynurenine pathway
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After the transformation of tryptophan into kynurenine, the action of enzymes along the
kynurenine pathway will then convert kynurenine into other catabolites [200, 201].
Kynurenine 3-hydroxylase (kynurenine 3-monooxygenase) converts KYN to toxic3hydroxyky-nurenine (3-HK) [198]. One of the end products is quinolinic acid (QUIN), an
agonist of the N-methyl-D-aspartate (NMDA)-sensitive glutamate receptors [202].
Another arm of the kynurenine pathway produces kynurenic acid (KYNA), which is an
endogenous antagonist of NMDA receptors. Moreover, KYNA can noncompetitively
block the activity of α7-nicotinic acethylcholine (α7-nACh) receptors [203-205].
Expression analysis indicates that the G protein-coupled receptor (GPCR) GPR35 is
selectively present in immune and intestinal tissues and is also a receptor of KYNA [206].
The KYN pathway has been widely studied in relation to neurodegenerative or
excitotoxic insults [207]. KYNA protects the central nervous system in excitotoxic
neurological diseases [198, 208] while quinolinic acid can act as a neurotoxin [209-213].
Various physiological and pathological processes are related to ‘‘kynurenines’’, the
collectively term of metabolites of kynurenine pathway [214].

1.6.1.2

IDO in the immune system and tumour immunity

Interest in the role of kynurenines in immune function has grown. Stone and coworkers
[209, 215] demonstrated that QUIN might play an important role in normal
immunosurveillance. In recent years, the role of kynurenine pathway in both the innate
and adaptive immune responses has been widely studied, and tryptophan metabolism and
kynurenine production reflect a crucial interface between the immune and nervous
systems [216].
In mammals, it is noteworthy that excess dietary tryptophan is not catabolized by IDO
through the kynurenine pathway. Tryptophan dioxygenase and nicotinamide adenine
dinucleotide levels are not maintained by synthesis, but by salvage. It implies that
tryptophan levels are maintained for purposes other than simply satisfying requirements
for protein synthesis. This was revealed by Munn and his colleagues in 1998, who also
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showed that IDO suppresses maternal T cell activity against embryonic tissues by
catabolizing tryptophan [217].
Since then, the role of IDO as a crucial enzyme in kynurenine pathway, and in
immunoregulation during infection, pregnancy, autoimmunity, transplantation and
neoplasia has been widely investigated [218, 219]. Recently, a novel enzymatic isoform
of IDO was described and termed indoleamine 2,3-dioxygenase-2 (IDO-2) (Ball et al.
2007, 2008). IDO and IDO-2 have a high degree of sequence homology (43% identity).
IDO-2 is predominantly expressed in murine kidney, liver, and in the male and female
reproductive system where, similar to the activity of IDO, it catalyzes oxidative cleavage
of a broad range of indole-bearing substrates [195, 220, 221].
In fact, the details of how IDO modulates the immune system are still not completely
clear. Two main theories have been proposed: the first pertains to starving cells of
tryptophan, while the other revolves around tryptophan metabolites. In the tryptophan
starvation theory, IDO has an effect on mammalian T cells similar to its effect in bacteria
[222, 223]. That is, tryptophan depletion induces cell cycle arrest in mammalian T
lymphocytes [220, 224] and makes these cells more vulnerable to apoptosis [225]. An
IDO-induced decrease in tryptophan concentration results in cell cycle arrest and anergy
(a state of unresponsiveness in peripheral T cells)[226, 227].
The tryptophan metabolite theory, on the other hand, is based on the observation that
certain downstream tryptophan-derived metabolites, mainly kynurenine, 3hydroxykynurenine, 3-hydroxyanthranilic acid, and QUIN are toxic to lymphocytes [228].
These molecules cause cell cycle arrest and apoptosis [229, 230], and can induce
differentiation of naive CD4+ T cells into immunosuppressive regulatory T cells
(Tregs)[231].
Much work has gone into understanding the relationship between IDO and tumour
immunity. IDO+ plasmacytoid dendritic cells (pDCs) are present in tumour lesions and in
tumour-draining lymph nodes (TDLNs) at sites of tumour growth in mice and humans.
Melanoma patients with abnormal accumulations of IDO+ cells with DC markers in
human sentinel LN draining sites had poorer clinical outcomes [98, 232].
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IDO also promotes tumour development through its effect on T cells. Cytotoxic TLymphocyte Antigen 4 (CTLA4+) Tregs ligate B7 on pDCs, maintaining IDO activity in
pDCs [233-235]. Blockade of CTLA4/B7 interactions had a significant impact on the
reduction of IDO enzymatic activity and Treg activation. IDO-activated Tregs mediated
suppression via a unique and distinctive mechanism that depended on intact programmed
death (PD)-1/PDL-1 signaling, which was not dependent on Interleukin 2 (IL-2), IL-10 or
transforming growth factor beta (TGF-β) [236, 237].
Increased expression of IDO through a pathway involving signal transducer and activator
of transcription 1 (STAT1) and nuclear factor kappa-light-chain-enhancer of activated B
cells (NF-κB) caused the loss of bridging integrator (Bin1)[238]. Bin1 loss is evident in
various cancers [219, 239], including those arising in breast [240], prostate [241], colon,
and lung [242]. Therefore, there is a link between loss of Bin1 and increased levels of
IDO. This link is tentative, however, and requires further investigation to be confirmed.
We used mannosed-liposome and IDO siRNA complexes to silence IDO expression in
DCs in melanoma-bearing mice. We hypothesized that this strategy would reinstall antitumour immunity and restrict melanoma xenograft growth through host mouse immune
activity.

1.6.2

Introduction to B-RAF

The RAS gene family harbours some of the most frequently-detected genetic alternations
in epithelial cancers and plays a central role in both normal and malignant cell growth
[243]. The first identified downstream effectors of RAS were the RAF serine/threonine
kinases [244-246]. There are three members in RAF family; A-RAF, B-RAF and C-RAF
(or RAF1), which have a high degree of homology in three conserved regions. Each
kinase has a RAS-binding domain and cysteine-rich domain that mediates interaction
with guanosine triphosphate (GTP)-bound RAS [247, 248]. In association with RAS,
RAF is recruited to the plasma membrane and the inhibitory intramolecular interaction of
the RAF catalytic domain with the NH2 terminus is diminished, leading to
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phosphorylation of sites located in the catalytic loop of the activation domain (Thr599
and Ser602 of B-RAF) [249]. Although all RAF isoforms are similar in these initiating
events, additional activation outside the catalytic domain (Tyr340, Tyr341, and Ser338 in
C-RAF) is required for full activation of A-RAF and C-RAF.
Since oncogenic B-RAF mutation was discovered in 2002, it stands as one of the most
powerful affirmations of the transformative potential of systematic cancer genome
characterization [250, 251]. Amino acid residues corresponding to sites of oncogenic
mutation in the B-RAF gene are either substituted with aspartic acids (Asp448 and
Asp449) or seem to be constitutively phosphorylated (Ser446) in tumour cells [252].
These changes highlight key events that reveal that B-RAF is the most important
physiologic mitogen-activated protein kinase (MAPK)/extracellular signal-regulated
kinase (ERK) kinase (MEK) activator. It is reported that MEK/ERK activation was
significantly disrupted in B-RAF -/- embryonic fibroblasts [253] but not in cells lacking
A-RAF or C-RAF [254], which further supports a predominant role for B-RAF as an
important MEK activator. Taken together, these data provide a mechanistic explanation
for the observation that B-RAF mutations, but not comparable mutations in the other
RAF proteins, are thought to underly the propensity of B-RAF for MEK/ERK activation.
B-RAF mutations have been reported to be present in over 70% of melanomas [255]. The
mutations are also found in premalignant atypical or dysplastic nevi, implicating B-RAF
activation as an initiating event in tumourigenesis [248, 256]. While there was a lower
frequency of B-RAF mutations in liver, pancreas, nonsmall cell lung cancer, glioma, and
acute myelogenous leukemia, a high frequency of B-RAF mutations were detected in
papillary thyroid carcinomas, serous ovarian cancers, and colorectal serrated
adenocarcinomas. Nearly 90% of B-RAF mutations are a T1799A transversion in exon
15 that results in Val600Glu (V600E) amino acid substitution, which leads to constitutive
kinase activation [257]. Interestingly, less than 1% of the melanomas carry both B-RAF
and RAS mutations (the latter occurring in more than 10% of melanomas), which
provides strong genetic evidence of direct RAS/B-RAF signaling pathway in this tumour
type. Moreover, even in cancers without RAS or B-RAF mutations, increased
RAF/MEK/ERK signaling can arise from other mechanisms [258, 259] including
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increased signaling from epidermal growth factor receptor (EGFR), human epidermal
growth factor receptor 2 (ERBB2 or HER2), platelet-derived growth factor receptor
(PDGFR), hepatocyte growth factor receptor (MET), and vascular endothelial growth
factor receptor (VEGFR), and loss of downstream negative regulators such as MAPK
phosphatase 3 (DUSP6) and RAF kinase inhibitor protein. Therefore, it is thought that
the majority if human tumours, not only those with RAS or B-RAF mutations, engage the
RAF/MEK/ERK signaling cascade. In general, B-RAF is an attractive therapeutic target
[260].
In our study, we used a lipid-based tumour-targeting siRNA delivery system and a local
topical siRNA delivery system to delivery B-RAF siRNA to cutaneous melanoma. We
hypothesized that these delivery systems can preferentially target tumour cells and
achieve B-RAF silencing in cutaneous melanoma, thereby restricting tumour growth.
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Chapter 2

2

A novel topical delivery reagent for siRNA-based
contact dermatitis therapy: preventing allergic
dermatitis by topical administration of MyD88 and
TNFα siRNAs

2.1 Summary
Topical delivery of siRNA is an attractive strategy to treat skin disorders that are resistant
to drug treatment, including allergic contact dermatitis (ACD). Topical siRNA has the
potential to specifically target critical disease-mediating RNAs while reducing the risk of
systemic toxicity. However, transdermal delivery of siRNA is challenging because of the
dense, occluding structure of the dermis and the chemical characteristics of siRNA. To
achieve cutaneous siRNA delivery for treatment of ACD and other skin diseases, a potent
transdermal enhancer is needed. ACD is a type IV delayed hypersensitivity initiated by
skin sensitization to an allergen. Understanding of the pathophysiology of ACD is
derived primarily from elucidation of events underlying contact hypersensitivity (CHS),
where skin inflammation is induced skin contact by haptens. TNFα and MyD88 are
inflammatory cytokines, involved in CHS progression, that are potential CHS treatment
targets. In this study, we develop and tested a novel topical delivery system for siRNAs
targeting TNFα (siTNFα) and MyD88 siRNA (siMyD88). The topical delivery system
resulted in in vivo mouse dermis cell gene silencing efficiency of 62% for siMyD88 and
54% for siTNFα siRNA, while siRNAs applied without the transdermal enhancer are
ineffective. Treatment with combined siMyD88 and siTNFα significantly attenuated CHS
symptoms in mice, better than treatment with siMyD88 or siTNFα as single agents.
Combined siMyD88 and siTNFα reduced inflammatory cell infiltration into skin and
local accumulation of CD8+ and CD4+ T cells. In summary, we have developed a novel
delivery system for effective delivery of siRNA into skin cells for relief of CHS
symptoms in mice. This is the first demonstration of topical gene silencing of TNFα and
MyD88 to treat allergic reactions, highlighting a potential clinical use of RNAi therapy
for skin and allergic diseases.
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2.2

Introduction

Topical delivery of therapeutic drugs is a particularly attractive strategy to treat skin
disorders [1]. It maximizes direct drug contact with target skin cells while minimizing
systemic exposure [2] as a method to increase treatment potency and reduce off-target
toxicity through high local (but low systemic) dosage, and to maximize ease of use [3].
However, cutaneous delivery of therapeutic agents is challenging due to tight packing of
corneocytes within a dense hydrophobic cellular matrix, and the dense network of
polysaccharides and fibrous proteins in the stratum corneum [4] all of which constitute a
physical barrier to drug entry. Potent transdermal delivery enhancers are essential to
facilitate drug uptake.
Contact dermatitis is an eczematous skin reaction caused by direct and usually repeated
exposure to harmful objects or chemicals. It is one of the most common skin diseases and
may vary from slight hyperkeratosis and small fissures to extensive redness, swelling and
scaling [5]. There are three types of contact dermatitis: allergic contact dermatitis (ACD),
irritant contact dermatitis, and photo-contact dermatitis. ACD is the most prevalent form
of immunotoxicity in humans, and is a Type IV delayed hypersensitivity reaction
mediated by hapten-specific T cells that generate inflammatory signals and induces
apoptosis in epidermal cells. Inflammation and apoptosis result in skin inflammatory
infiltrate and adverse clinical symptoms [6]. There are two phases during this process: the
the sensitization phase and the elicitation phase. The sensitization phase occurs after the
first contact of the hapten and the skin. The elicitation phase is also known as challenge
phase, which occurs when the haptens challenge the sensitized individuals [7]. Our
understanding of ACD derives from experiments undertaken in an animal contact
hypersensitivity (CHS) model. In this study we use 1-fluoro-2, 4-dinitrobenzene (DNFB)induced CHS (a well-established animal CHS disease model) to explore the efficacy of a
novel siRNA topical delivery vehicle, and targeting of TNFα and MyD88, to treat ACD.
RNAi is an endogenous mechanism in which double-stranded RNA knocks down the
expression of homologous genes to induce gene silencing. Since it was first observed in
late 1980s, it had been used as a powerful laboratory technique to explore gene function
[8]. Recent research on animal disease models of cancer, viral infection, age-related
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macular degeneration, and other pathological conditions has resulted in development of
RNAi molecules for treatment of human diseases. However, the lack of specific and
effective in vivo delivery methods is a major impediment to clinical application [9, 10].
Tumor Necrosis Factor alpha (TNFα) is a systemic cytokine mediating inflammation.
TNFα activates neutrophils, up-regulates endothelial adhesion molecules, increases
capillary permeability, and exerts direct cellular toxic effects [11]. In the CHS model,
release of TNFα can activate local endothelial cells and facilitate T cell recruitment [11,
12].
The Myeloid Differentiation primary response gene 88 (MyD88) is critical for signaling
from all Toll-like receptors (TLRs) except TLR3 [13]. MyD88 is expressed in a variety
of human and murine tissue albeit at varying levels [14]. It involves Toll/interleukin-1
receptor (TIR) signaling pathway, which results in NF-кB activation, cytokine secretion
and inflammatory response. Recently, Paul A. Klekotka’s study shows that MyD88
deficient mice were unable to mount an CHS model response [15].
In this study, we describe a novel topical RNAi delivery therapy for CHS. We report that
topical administration of siRNA encapsulated in the new delivery vehicle silences
expression of MyD88 and TNFα in dermal cells and inhibits progression of CHS by
reducing local accumulation of inflammatory CD4+ T cells and CD8+ T cells.

2.3
2.3.1

Materials and Methods
Chemicals

1,2,3-Propanetriol (glycerol) and 1-fluoro-2,4-dinitribenzene (DNFB) were purchased
from Sigma-Aldrich, Inc. (Oakville, Ontario, CA). Dimethyl sulfoxide (DMSO) was
purchased from Caledon Laboratory Chemicals, Inc. (Georgetown, Ontario, CA) and
lipofectamine 200 (L2K) was purchased from Invitrogen Life Technologies, Inc.
(Burlington, Ontario, CA).Glycerol was purchased from VWR International, Inc.
(Edmonton, Alberta, CA)
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2.3.2

Mice

BALB/c mice (male, 6-8 weeks old) were purchased from Jackson Laboratory (Bar
Harbor, ME, USA) and maintained under pathogen-free conditions in the barrier facility
at The University of Western Ontario. All experiments were performed in accordance
with the Guide for the Care and Use on Animals Committee Guidelines and standard
operating procedures as required by the Animal Use Subcommittee of The University of
Western Ontario.

2.3.3

siRNAs

Double-stranded siRNAs targeting murine TNFα siRNA (siTNFα) and MyD88 siRNA
(siMyD88), and control non-targeting scrambled siRNA (siScramble) were obtained from
Dharmacon, Inc. (Lafayette, CO, USA). The sequences were:
siTNFα:

sense, 5’-GACAACCAACUAGUGGUGC-3’
antisense, 5’-GCACCACUAGUUGGUUGUC-3’

siMyD88:

sense, 5’-CAGCGAGCUAAUUGAGAAAUU-3’
antisense, 5’-UUUCUCAAUUAGCUCGCUGUU-3’

siScramble:

sense, 5’-CGUACGCGGAAUACUUCGA-3’
antisense, 5’-CGTACGCGGAATACTTCGA-3’

2.3.4

In vitro silencing of TNFα and MyD88

B16F10 cells were transfected with siTNFα and siMyD88 using L2K. Untreated cells and
cells transfected with siScramble were used as controls. Briefly, cells were plated in 24well plates (1.5×105 cells per well) and allowed to grow for approximately 16 h (80%
confluence), transfected with siTNFα (1 μg/well) and/or siMyD88 (1 μg/well) in 500 l
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serum-free medium for 4 h, and then incubated in complete medium for 24 h. Cells were
then harvested for RNA isolation.

2.3.5

TNFα and MyD88 mRNA measurement

After in vitro transfection with siTNFα or siMyD88, total tissue or cellular RNA was
isolated using Trizol (Invitrogen, Burlington, Ontario, CA) and used as a template for
cDNA synthesis and non-quantitative PCR and quantitative PCR (qPCR). qPCR
reactions were performed as described previously [16] using gene-specific forward and
reverse primers (100 nM each) and SYBR Green PCR Master mix (Stratagene, La Jolla,
CA) in a Stratagene MX 4000 Multiplex qPCR System. Primers used for the
amplification of murine TNFα, MyD88 and GAPDH (control to assess relative levels of
TNFα and MyD88 mRNA) were:
TNFα: forward, 5’-CTCCCTCCAGAAAAGACACCAT-3’
reverse, 5’-ATCACCCCGAAGTTCAGTAGACAG-3’
MyD88:

forward, 5’-TAGACCGTGAGGATATACTGAAGG-3’
reverse, 5’-TTAGCTCGCTGGCAATG-3’

GAPDH:

forward, 5’-TGATGACATCAAGAAGGTGGTGAA-3’
reverse, 5’ -TGGGATGGAAATTGTGAGGGAGAT-3’

2.3.6

Development of topical siRNA delivery reagent

Fluorescently-labeled siRNAs with or without candidate topical transdermal delivery
vehicle, and candidate transdermal delivery vehicles alone, were prepared as follows:
A: L2K (5 l+ 15 μl nuclease-free water (NFW))
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B: Glycerol (5 l+15 l NFW)
C: L2K (1 l)+Cy3 siRNA (2 g/8 l NFW)+NFW (11 l)
D: Glycerol (5 l)+Cy3 siRNA (2 g/8 l NFW)+NFW (7 l)
E: L2K (1 l)+Glycerol (5 l)+Cy3 siRNA (2 g/8 l NFW)+NFW (6 l)
F: DMSO (5 l)+Cy3 siRNA (2 g/8 l NFW)+NFW (7 l)
G: L2K (1 l)+Glycerol (5 l)+DMSO (5 l)+NFW (9 l)
H: L2K (1 l)+DMSO (5 l)+Cy3 siRNA (2 g/8 l)+NFW (6 l)
I: Glycerol (5 l)+DMSO (5 l)+Cy3 siRNA (2 g/8 l)+NFW (2 l)
J: L2K (1 l)+Glycerol (5 l)+DMSO (5 l)+Cy3 siRNA(2 g/8 l)+NFW (1 l)
Each was applied onto the shaved dorsal skin of CD1 mice in a 0.5 mm2 area. Mice were
sacrificed and dorsal skin resected and fixed in OCT for cryosectioning. Fluorescent was
observed microscopically to assess cell and tissue uptake of a model fluorescentlylabeled but non-targeting siRNA.

2.3.7

Preparation and application of a topical delivery reagent for
CHS

Glycerol (8 l), DMSO (1 μl), L2K (1 l) and 8 μl NFW water Glycerol (8 l), DMSO (1
μl), L2K (1 l) and 2 μg siTNFα diluted in 8 μl NFW water or Glycerol (8 l), DMSO (1
μl), L2K (1 l) and 2 μg siMyD88 diluted in 8 μl NFW water or Glycerol (8 l), DMSO
(1 μl), L2K (1 l), 1 μg siMyD88 and 1 μg siTNFα diluted in 8 μl NFW water were
mixed and applied in mouse right ear in each treatment group. Reagents were applied
from day1 and applied once/day for 4 days.
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2.3.8

Assessment of siRNA stability in serum

SiRNA (0.3 μg) was mixed with novel reagents and incubated in fetal bovine serum (FBS)
20l (Gibco, Burlington, ON, CA) for 1, 2, 3, and 4 h. The mixture was collected at each
time point and siRNA degradation was assessed by loss of intensity of bands visualized
by gel electrophoresis.

2.3.9

Mouse CHS model and siRNA administration

DNFB (25 μl of a 0.5% solution in acetone/olive oil [4:1]) was applied to both right and
left mouse ears on day 0 and day 1 (the second application was to the same area as the
first) to generate CHS model conditions. DNFB (10 μl of 0.2% in 4:1 actone/olive oil)
was applied to the same region on the right ear only on day 5 as an immunogenic rechallenge (the immunogen application area on the left ear was re-challenged with vehicle
only). SiRNAs in each candidate topical application vehicle was applied after the DNFB
application (4 hours post DNFB application) on day 1. SiRNAs in each candidate topical
application vehicle was applied to the immunogen application on the right ear only on
days 1, 2, 3, and 4. Experimental groups were:
1. Untreated control
2. DNFB alone without siRNA treatment
3. DNFB with topical delivery reagent alone
4. DNFB with siTNFα (2 μg) in candidate topical delivery reagent
5. DNFB with siMyD88 (2 μg) in candidate topical delivery reagent
6. DNFB with both siTNFα (2 μg) and siMyD88 (2 μg) in candidate topical delivery
reagent.
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2.3.10

Assessment of the degree of DNFB-induced CHS

Ear swelling: Mouse ear thickness was measured 48 h after the last DNFB hapten
treatment. Net ear swelling was the thickness of the DNFB-treated ear (measured 48 h
after the final DNFB treatment) minus the thickness of the vehicle-treated ear measured
at the same time.
Redness and scaling: Redness and scaling in each ear were subjectively assessed by 2
independent observers on a scale of 1 to 9 (9 being the greatest amount of redness or
scaling and 1 the least) daily from day 1 to 8. The first measurement was finished 24 h
after the first DNFB application and before the second DNFB application. Each category
has maximally three scores; therefore the highest score will be 9 in this scoring system.
The scores for each of the three symptom categories (redness, swelling, and scaling) were
added to provide an overall estimate of CHS symptom intensity. Differences between and
among treatment and control groups were analyzed for significant differences indicative
of the capacity of siRNAs targeting TNFα and/or MyD88 to alleviate CHS symptoms.

2.3.11

Assessment of neutrophil infiltration into dermis

24 h post challenge, skin from treated ear regions were dissected from mice, fixed in 10%
formalin, embedded in paraffin, sectioned (5 μm) and Hematoxylin and eosin (H&E)
stained, in which basophilic white blood cells stain dark blue and eosinophilic white
blood cells stain bright red, neutrophils stain a neutral pink.

76

2.3.12

Immunohistochemical visualization of CD4+ CD8+ T cells in
skin

Skin tissue was fixed in OCT to obtain frozen sections. Sections were incubated with
primary αCD4 and αCD8 MAbs (Abcam, Cambridge, USA, diluted 1:100), incubated
with biotinylated secondary Ab (45 min), and then with horseradish peroxidase-labeled
streptavidin (37◦C, 45 min). Slides were diaminobenzidene (DAB)-stained and
counterstained with hematoxylin.

2.3.13

Statistical analysis

All data are presented as mean of n measurements ± SD. Statistical comparisons between
groups were performed using Student’s t-test. Statistical significance was determined a
priori to be achieved when p<0.05.

2.4
2.4.1

Results
Development of a new topical reagent for siRNA delivery

Transdermal delivery was, at one time, sufficiently problematic that intact skin was
considered to be completely impermeable to all substances [17]. The greatest barrier to
transdermal delivery is the tight structure of the stratum corneum (SC) in epidermis. The
SC is composed of both keratin-rich corneocyte and the hydrophobic lipid-rich matrix
which serve as the “bricks” and “mortar” of SC [1]. To test the capacity of candidate
delivery agents, we compared the ability of those agents to deliver siRNA into and
through skin. Candidate reagents were mixed with Cy3-labelled siRNA and applied to a
fixed area (0.5 cm2) of dorsal skin on live mice.
L2K is a well-established and widely used reagent for gene transfection in vitro [7].
Glycerol is a common ingredient in many skin medicines [8]. Firstly, it has to be
confirmed that L2K and glycerol alone did not display auto-fluorescence (Fig. 2-1A&B).
L2K alone did not deliver siRNA through the stratum corneum and into dermis (Fig. 2-
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1C). Glycerol as a single agent delivered siRNA into dermis (Fig. 2-1D). A combination
of glycerol and L2K increased the amount of siRNA delivered into dermis, and did so to
a greater degree than glycerol or L2K alone (i.e., the degree of fluorescence due to the
presence of Cy3-labeled siRNA was greater) (Fig. 2-1E). These data support the
hypothesis that glycerol combined with L2K is the most effective facilitator of siRNA
entry into dermis compared to either reagent alone.
DMSO is a universal drug delivery reagent successfully used in many in vivo drug
delivery systems [18, 19]. It is comfirmed that DMSO combine with L2K and glycerol
has no auto-fluorescent (Fig1 2-1G). DMSO alone delivered Cy3-labeled siRNA into
skin, to a degree similar to that observed with glycerol alone (Fig. 2-1F). However, the
pattern of delivery suggested that delivery efficiency was uneven and irregular compared
to glycerol (i.e., some dermis regions received high levels of siRNA while others
received little). DMSO combined with L2K facilitated transfer of Cy3-labeled siRNA
into dermis, although a large fraction of applied siRNA remained on the skin surface
without penetrating deeply (Fig. 2-1H). A combination of DMSO and glycerol facilitated
siRNA transfer into dermis better than other single transfer reagents or two reagent
combinations (Fig. 2-1I). However, the most effective Cy3 siRNA transfer (i.e.,
fluorescent staining in dermis) was mediated by combining glycerol, DMSO, and L2K
(Fig. 2-1J). These data support the hypothesis that a combination of glycerol, DMSO, and
L2K is the most efficient combination of delivery agents among those tested for transfer
of siRNA across the stratum corneum and into dermis.

2.4.2

Optimization of glycerol:L2K:DMSO siRNA delivery reagent

We further optimized the glycerol:L2K:DMSO topical siRNA delivery reagent
combination by testing the relative capacity of different glycerol:DMSO ratios (v/v) to
deliver Cy3-labeled siRNA to dorsal mouse skin dermis. Lower glycerol concentrations
were relatively ineffective while increased glycerol with decreased DMSO enhanced
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Figure 2-1 Development of a novel topical delivery adjuvant for siRNA. The indicated
reagents (combinations A-J, as described in the text) were mixed and 20 l applied to
mouse skin, as described in Materials and Methods. Mice were euthanized at 4 h posttreatment and skin collected for bright field and fluorescent microscopy. Fluorescence
indicates the presence of Cy3-labeled siRNA.
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siRNA delivery. Considering that DMSO may cause skin irritation if absorbed through
skin, and increased viscosity could facilitate penetration by prolonging residency of the
mixture on the skin surface, we tested additional glycerol:DMSO ratios and observed
that ratios of 9:1 retained a high level of penetration without inducing skin rash. We
concluded that the optimal combination for glycerol:DMSO:L2K:siRNA solution was
9:1:1:8 in a volume ratio(Fig. 2-2). In this experiment, 2 g siRNA dissolved in 8 l
NFW was used as siRNA solution.

2.4.3

TNFα and MyD88 knockdown in vitro and in vivo

To validate the efficacy of siRNAs selected to knock down MyD88 (siMyD88) and
TNFα (siTNFα), we transfected mouse melanoma cells (B16) in vitro which each siRNA.
MyD88 and TNFα mRNA levels were largely decreased 24 h post-transfection in B16
cells (Fig. 2-3A). Thus, the siRNAs selected to reduce each of these mRNA targets are
effective.
To evaluate in vivo gene silencing after topical delivery of siMyD88 and siTNFα on mice
dorsal skin, we prepared glycerol:DMSO:L2K:siRNA (9:1:1:8) and apply it topically to
dorsal mouse skin. The mice were sacrificed 24 h after application and skin was collected
for determination of target mRNA levels. MyD88 and TNFα mRNA were reduced by
62% and 54% respectively (Fig. 2-3B, C).
Another consideration is that siRNA might be easily degraded in the topical application.
To clarify whether the reagent may facilitate protection of RNA degradation, we mixed
siRNA prepared with topical reagent or without topical reagent with freshly-prepared
mouse plasma (rich in RNases). Undegraded siRNA was visualized by electrophoretic
mobility at various incubation times. Compared to naked siRNA, the topical delivery
reagent successfully protected siRNA from degradation (Fig. 2-3D).
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Figure 2-2 Optimization of topical siRNA delivery using a combined glycerol:DMSO
cocktail. L2K (1 μl) and Cy3-labeled siRNA (8 μl) were mixed with glycerol and DMSO
at the indicated volume ratios and applied to mouse skin as described in Materials and
Methods. Mice were sacrificed 4 h post-treatment and skin was collected for bright field
and fluorescent microscopy. Fluorescence indicates the presence of Cy3-labeled siRNA.
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Figure 2-3 siRNA-mediated gene silencing of MyD88 and TNFα in vitro and in vivo. (A)
In vitro silencing efficacy of siMyD88 and siTNFα siRNA: B16F10 cells were cultured
and transfected with siRNAs targeting MyD88 and/or TNFα, or control, non-targeting
siRNA (siScramble). MyD88 and TNFα mRNAs were measured relative to GAPDH
mRNA at 24 h post-transfection by RT-PCR and gel electrophoresis as described in
Materials and Methods. (B, C) In vivo silencing of MyD88 and TNFα in skin: siMyD88,
siTNFα, or siScramble were mixed with the novel delivery reagent
(glycerol:DMSO:L2K:siRNA = 9:1:1:8) and applied to mouse skin. Mice were
euthanized and skin collected at 24 h post-treatment. The levels of MyD88 and TNFα
mRNA were determined by qPCR as described in Materials and Methods. Relative
quantity of MyD88 and TNFα mRNA was expressed as mean ± SD. *Student's t-test,
p<0.05. (D) Delivery reagent protection of siRNA from serum-mediated degradation: The
novel reagent and 0.3 g siRNA were mixed with 20μl FBS and incubated in 370C for 1,
2, 3, or 4 h. Integrity of siRNA was detected by gel electrophoresis as described in
Materials and Methods.
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2.4.4

Attenuation of CHS by topical treatment with siMyD88 and
siTNFα in delivery reagent

DNFB is commonly used to induce model contact dermatitis in mice [20, 21],
characterized by swelling, redness and scaling [5]. We hypothesized that silencing of
MyD88 and TNFα in local skin tissue would reduce both swelling [22] and the severity
of other symptoms due to reduction in cell-mediated responses mediated by MyD88 and
TNFα during CHS sensitization phase [15]. To this end we applied freshly-prepared
topical delivery agent with siTNFα and/or siMyD88 daily to the skin of mice. After 4 d
treatment with siMyD88 or siTNFα alone, or siMyD88 combined with siTNFα, the
overall clinical symptoms of redness, swelling and scaling (as assessed by subjective
inspection of skin sections) were decreased compared to CHS treated with topical
delivery reagent alone or untreated CHS (Fig. 2-4A).
Ear swelling was reduced in groups treated with either single siRNA, implying that
siTNFα and siMyD88 alone have protective and/or ameliorative capacity. Silencing of
TNFα to reduce swelling of CHS has been reported and our result is consistent with that
report [22]. On the other hand, use of siMyD88 to reduce swelling is reported by us for
the first time. However, redness and scaling were reduced to only a minor degree by
treatment with either siRNA alone. Combined siTNFα and siMyD88 treatment reduced
swelling 48 h after re-challenge, compared to treatment with siTNFα or siMyD88 alone
(Fig 2-4B).
To have an overall and real time assessment of symptom including swelling, redness and
scaling in different groups from day1 to day 8, we created a scoring system to assess the
severity of CHS and applied that system to quantitate siRNA-mediated CHS symptom
changes (after transfer of siRNAs, alone or in combination, in the glycerol:L2K:DMSO
topical delivery reagent). Score from day1 is assessed 24 h after first DNFB application
and before first treatment. Quantitative assessment revealed that reagent alone exerts a
capacity to reduce CHS symptoms, implying that topical delivery reagent was both nontoxic and therapeutic. Both single siRNA treatments (siTNFα alone or siMyD88 alone)
have significantly attenuated the symptoms 24 h after the re-challenge. However, siTNFα
alone could also significantly release the overall symptom 48 h after the second
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Figure 2-4 Attenuation of CHS by topical delivery of siMyD88 and siTNFα: (A) CHS
symptom severity in experimental and control groups: CHS was induced with DNFB as
described in Materials and Methods. CHS in mouse ears was treated by topical
application of glycerol:DMSO:L2K:siRNA (9:1:1:8) alone (Reagent) or containing
siMyD88 + siTNFα, siMyD88 alone, or siTNFα alone. Control mice were left untreated
with DNFB and did not suffer from CHS (Naïve reagent). All reagent and siRNA
treatments were once per day for 4 days. Severity of symptoms was assessed 48 h after
re-challenge with DNFB on day 4. (B) Quantification of swelling during CHS: Ear
thickness was measured 48 h after re-challenge with DNFB on day 4. Net swelling
thickness = (thickness, hapten re-challenged ear, μm) - (thickness, vehicle-treated ear,
μm). *Student's t-test, p<0.05.
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application of DNFB. Therefore, single siTNFα treatment can reduce the symptoms both
in sensitization phase and elicitation phase while single siMyD88 treatment only reduce
symptoms in elicitation phase. Combining siTNFα and siMyD88 resulting in alleviation
of CHS symptoms to a greater degree than single siRNA treatment groups. The
combination significantly attenuated the symptoms since 48 h after the first DNFB
application and last for over 72 h after re-challenge, which covers nearly the whole
sensitization phase and elicitation phase. When compare to single siRNA treatment, the
severity of symptoms in combination treatment group significantly less from 24 h post rechallenge to 72 h post re-challenge. These data suggest that simultaneous suppression of
both TNFα and MyD88 provides a therapeutic advantage in preventing development of
CHS symptoms and/or reducing their severity, over reduction of either target alone and
particularly after repeated exposure to hapten (Fig. 2-5C).
The number of infiltrating neutrophils in tissues affected by CHS is closely related to the
severity of symptoms [22]. The H&E staining for the part in each group that carries most
severe symdrom is shown in (Fig. 2-5D). Neutrophils are among the most important
initiators and effectors of CHS [9]. To determine whether treatment with siMyD88 and
siTNFα can reduce neutrophil infiltration in CHS, we treated ears of mice with siRNA in
topical delivery reagent and quantitatively scored CHS symptoms (Fig. 2-5C) and
subjectively observed neutrophil infiltration (Fig. 2-5D) at 48 h after DNFB rechallenge.
Treatment with topical delivery reagent alone reduced swelling slightly (Fig. 2-5C) but
did not reduce neutrophil infiltration (Fig. 2-5D). Treatment with single siRNAs reduced
neutrophil infiltration in CHS compared to untreated CHS or CHS treated with topical
delivery reagent alone (Fig. 2-5D). Combined treatment with both siTNFα and siMyD88
were subjectively more effective at reducing neutrophil infiltration than treatment with
single siRNAs (Fig. 2-5D). These data reveal that neutrophil infiltration in CHS can be
reduced or prevented by down-regulation of MyD88 and TNFα through topical delivery
of siRNAs. Moreover, the epidermis thickness obviously increased and Eosinophils cell
clusters can clearly be seen. While this change is lighter in single treatment group, the
combination treatment is mostly similar to naïve group (Fig. 2-5D).
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Figure 2-5 Attenuation of CHS by topical delivery of siMyD88 and siTNFα. (C) CHS
symptom severity in control and treated skin: Summary scores of CHS symptoms
(redness, swelling, scarring) were evaluated from day 1 to day 8 as described in Materials
and Methods. The data presented are from one of three independent experiments (n=6
mice/group). *Student's t-test, p<0.05. (D) Neutrophil infiltration: CHS was induced in
mouse skin and treated with siTNFα and siMyD88 as described in (C). Mice were
euthanized 48 h post-rechallenge and skin collected for microscopic analysis of
neutrophil infiltration, as described in Materials and Methods.
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2.4.5

Immune suppression by topical delivery of siMyD88 and
siTNFα

It is believed that CD4+ cells and CD8+ cytotoxic T cells are important factors in CHS
[20, 21, 23]. They accumulate locally in regions in direct contact with hapten and play a
major role in triggering CHS. To assess whether treatment with siRNAs targeting TNFα
and/or MyD88 modulated accumulation of these cells in CHS, mouse ear tissue was
obtained after induction of CHS and 48 h after hapten rechallenge, and CD8+ and CD4+ T
cell accumulation assessed by immunostaining. Obvious accumulation of CD8+ and
CD4+ T cells was observed in untreated CHS. Treatment with single siRNAs (either
siTNFα for siMyD88) reduced CD8+ (Fig. 2-6A) and CD4+ (Fig. 2-6B) T infiltration, but
incompletely. The combination treatment with both siRNAs almost completely prevented
infiltration by CD8+ and CD4+ T cells (Fig. 2-6A,f; Fig. 2-6B,x). These data suggest that
topical delivery of siMyD88 and siTNFα can prevent accumulation of CD4+ and CD8+ T
cells that contribute to CHS severity.
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Figure 2-6 Immune suppression by topical delivery siMyD88 and siTNFα. (A) CD8+ T
cell accumulation: Mice were treated with DNFB to induce CHS and re-challenged 4 d
later with DNFB. At 48 h after re-challenge, mice were euthanized and skin was collected
and stained with antibodies to detect CD8+ T cells: (a) Non treatment naïve mice; (b)
mice with CHS without any treatment; (c) mice with CHS treated with reagent alone; (d)
mice with CHS treated with reagent with siTNFα alone; (e) mice with CHS treated with
reagent and siMyD88 alone and (f) mice with CHS treated with reagent mixed with
siMyD88+siTNFα show the CD8+ cells. (B) CD4+ T cell accumulation. Skin sections
were made as decribed above, and stained with CD4+ cells: T (g) Non treatment mice; (h)
mice with CHS without any treatment; (i) mice with CHS treated with reagent alone; (j)
mice with CHS treated with reagent with siTNFα alone; (k) mice with CHS treated with
reagent and siMyD88 alone; (l) mice with CHS treated with reagent mixed with
siMyD88+siTNFα represent the CD4+ positive cells. Pictures were taken under the
microscope in 100 time magnification. The data presented complied results from 3
experiments.
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2.5

Discussion

Topical delivery of siRNA has important advantages: First, it could directly target the
cells in the disease site. Second, there is minimum worry about the risk of systemic side
effects. Third, it is easy for administration since it is noninvasive, painless and readily
accessible nature.
However, the resilient barrier of the epidermal layers of the skin, primarily the stratum
corneum, prevents the diffusion of exogenous chemical agents, which makes skin graft a
significant obstacle to dermal and transdermal drug delivery [24]. Also, siRNA itself is
difficult to be absorbed by skin and it is not stable enough [25]. Moreover, siRNA is
negative charge which makes it being repelled by the cell membrane (also negative
charge), and its size is relatively large makes it difficult to penetrate the cell. Even the
siRNA successfully enters into cells, it might also face challenges as endosomal escape
[1]. Various physical and chemical methods have been applied in previous study for
overcoming the skin barrier while limiting the damage to the skin. Several studies has
report the intradermal injection of DNA or siRNA in mouse skin model [1, 26-29].
However, transdermal injection can only be applied in small area of the skin and it is
actually not user friendly and painful if multiple injections are necessary. To reduce the
pain, needless injector which could generate high pressure beam of injection for physical
penetration [30], or low frequency sonophoresis have been applied for transdermal
delivery [31]. However, needless injector carries the sample problem of intradermal
injection as they only able to cover small area of the skin, which limits their application.
The sonophoresis technic needs the carrier of special equipment which could be costly
while compare to chemical transdermal methods. Other study reported chemicals as
acetone to weaken the stratum corneum, thus to facility the drug delivery. However, it is
potentially harmful to skin since it is difficult to control the intensity of the weaken
process [32].
In this study, we create a novel reagent which could not only efficiently carry siRNA
penetrating the stratum corneum, but also could help siRNA transfecting the cells in skin
and achieve silencing.
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We optimize the ratio between the components of the novel reagent to minimize the
irritation to skin while maximally keeping the ability of penetration (Fig2). Base on the
thickness measurement data and the score of syndromes in various experimental groups,
the reagent control has lighter syndromes when compare to non-treatment group, which
implies our reagent has certain level of protection function while apply on CHS mouse
skin. It is reasonable since our reagent contains majority of glycerol, which plays a role in
skin as hydration, cutaneous elasticity and epidermal barrier repair. As a lubricant, it has
been applied in lots of commercial available skin care products [33]. The majority of
glycerol in the combination makes the novel reagent retains a certain level of viscosity,
which prevents the fast evaporation of the delivery combination and provides longer time
for penetration. And solvent viscosity results in friction against proteins in solution, and
this should result in decreased motion, inhibiting catalysis in motile enzymes [34], which
might contribute to the stability of the siRNA in skin. DMSO is an important polar
aprotic solvent that dissolves both polar and nonpolar compounds and is miscible in a
wide range of organic solvents as well as water. It has a distinctive property of
penetrating the skin very readily. However, topically apply DMSO alone can arose skin
irritation, which has been observed in our study. L2K is well established as a reagent for
in vitro siRNA delivery. It can condense with siRNA and brings them into cells
efficiently. The novel reagent adopts the advantages of each component and minimized
their weaknesses, which makes itself a powerful reagent to deliver various siRNA into
skin layers and against various kinds of dermatologic diseases. Since RNAi owns the
characteristic of specifically knock down the target genes, our therapy also displays a
potential application in treating diseases with strong drug resistant.
The DNFB induced CHS mouse model has been extensively studied and termed a Type
IV delayed hypersensitivity reaction involving a cell-mediated allergic response. CHS
arises as a result of two essential stages: An induction phase, which primes and sensitizes
the immune system for an allergic response, and an elicitation phase, in which this
response is triggered. In induction phase, contact allergens are able to cross the stratum
corneum of the skin then the haptens will associate with epidermal proteins forming
hapten-protein conjugates. The conjugate formed is then recognized as a foreign body by
the MHC class I- expressing langerhans cells (LCs) (or Dendritic cells) [21]. Then the
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LCs will internalize the protein; transport it via the lymphatic system to the regional
lymph nodes; and present the antigen to T-lymphocytes. In the lymph glands, the
differentiated DCs present the allergenic epitope, associated with the allergen, to T
lymphocytes. These T cells then divide and differentiate, clonally multiplying so that in
the elicitation phase when the allergen is experienced again by the individual, these T
cells will respond more quickly and more aggressively. It is showed that both CD4+ Thelper 1 (Th1) and CD8+ cytotoxic T-cells (Tc1) cells are crucial effectors in the CHS
response to DNFB [23]. The CD8+ effector T cells migrate to the challenged site and
initiate the skin inflammation via Fas and/or perforin-mediated cytolytic function [20, 35,
36]. CD4+ T lymphocytes secreting IL-2 and IFN-γ play a preeminent role in the
evolution of CHS. In this study, we treat mice after induction phase and before the
elicitation phase. Our result agrees with these reports: compare to control group, there are
less CD4+ CD8+ T cell accumulation in siTNFα and siMyD88 treatment group 48 h post
challenge in the place where the reaction was triggered.
TNFα is a very important mediator, which activates local endothelia to facilitate T cell
recruitment[37, 38]. TNFα can also activate NF-kappa B which leads to the production
and secretion of more inflammatory cytokines (IL-1, IL-6). Some study reported that
TNFα level correlates with swelling, which is the classical manifestation of contact
hypersensitivity. TNFα also closely related to the density of dermal infiltration [39].
Contact hypersensitivity initiates with innate immune reaction and results in an adaptive
immune response. Toll like receptors constructs a vital important signal pathway for cells
of innate immune system. MyD88 is the adaptor protein for all TLR members except
TLR3. MyD88 associates with the Toll/interleukin-1 receptor (TIR) domain of TLRs, the
interleukin-1 receptor-associated kinases IRAK1 and IRAK4, and tumor necrosis factor
receptor-associated factor 6 (TRAF6) [40]. This interaction results in NF-кB activation,
cytokine secretion and inflammatory response. Recently study report that IL-1R and IL18R/MyD88 pathways are required in distinctly different cells during the sensitization
phase of CHS [41].
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In current view, human ACD is a disease that once established, and then it lasts a lifelong.
The only available etiologic treatment of ACD is elimination of the contact allergen [6].
Locally application of corticosteroids that targets lymphocyte activation remains the main
approaches for ACD. However, corticosteroids has lots of side effects, such as cutaneous
addiction, hyperglycemia, insulin resistance, diabetes mellitus, osteoporosis, cataract,
anxiety, depression, colitis, hypertension, ictus, erectile dysfunction, hypogonadism,
hypothyroidism, amenorrhoea, and retinopathy [42]. Our study provides a possibility of a
new therapy for ACD, which is protective, potent and user-friendly.
In conclusion, we report here a novel reagent that composed of glycerol, DMSO and L2K
can effectively delivery siRNA into deep skin layer and achieve gene silencing, which
leads to the syndrome attenuation of DNFB induced contact hypersensitivity, reduced
inflammation cells infiltration and CD4+ CD8+ accumulation.
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Chapter 3

3

Targeted siRNA silencing of IDO in dendritic cells
using mannose-conjugated liposomes: a novel
strategy for treatment of melanoma

3.1 Summary
Indoleamine 2, 3-dioxygenase (IDO) expressed in antigen presenting cells (DCs) blocks
T cell activation, induces T cell apoptosis, and promotes T cell differentiation into
regulatory T cells (Tregs) that help tumor cells escape immune surveillance. Mannose
receptors are highly expressed in antigen-presenting cells (APCs). In this study, we
developed a novel APC-targeted siRNA delivery system using mannosed liposomes
(Man-lipo) with encapsulated IDO siRNA (Man-lipo-siIDO), which preferentially knocks
down IDO in melanoma bearing mice draining lymphnode and spleen. Mice treated with
Man-lipo-siIDO had a delayed time of onset of implanted murine melanomas, increased
survival time, reduced tumor size, and increased reactivity of T cells from spleen and
lymph nodes against melanoma antigens. The enhanced anti-tumor immunity may be
causally associated with inhibition of apoptosis in CD8+ and CD4+ T cells as well as Treg
cells in spleen and lymph nodes. This study is the first to demonstrate that Man-liposiIDO can preferentially target DCs and efficiently silence IDO expression in vitro and in
vivo, events expected to enhance anti-tumor immune reactions against melanoma
xenografts. This study supports the hypothesis that Man-lipo-siIDO may have potential
for development as an immune-targeting therapeutic anticancer agent.

3.2

Introduction

Immune evasion and T cell tolerance induction have an important role in neoplastic
growth, and recently, increasing evidence has demonstrated that tryptophan catabolism
has a part in immune evasion. Indoleamine 2, 3-dioxygenase (IDO) is the first and rate
limited enzyme that degrades tryptophan alone in kynurenine metabolic pathways. IDO
plays an important role in immuno-regulation during infection, pregnancy, induction of
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autoimmune events, transplantation, and neoplasia [1-3]. By depleting tryptophan, IDO
induces cell cycle arrest in T lymphocytes and makes these cells more vulnerable to
apoptosis, which subsequently leads to the attenuation of the immune system [1, 4, 5]. In
addition, metabolic products generated by IDO, including kynurenine, 3hydroxykynurenine, 3-hydroxyanthranilic acid, and quinolinic acid, can cause cell cycle
arrest and apoptosis [6]. Moreover, IDO can also induce differentiation of naive CD4+ T
cells into regulatory T cells (Tregs) that further suppress anti-tumor immune responses [7,
8]. A recent clinical study reported strong expression of IDO in malignant melanoma
metastases that correlated with a high density of Foxp3-positive Treg cells and was
associated with decreased survival times [9].
RNAi is an endogenous mechanism in which double-stranded RNA specifically knocks
down the expression of target genes to induce partial or complete gene silencing. Small
interfering RNA (siRNA), a mediator of RNAi, has been used as a powerful laboratory
tool to reduce or ablate gene expression [10]. Recently, investigation of RNAi
applications in animal models of human diseases including cancer, viral infection, and
age-related macular degeneration has moved RNAi forward into clinical applications.
However, the lack of specific and effective in vivo delivery methods reduces the potential
effectiveness of siRNA-based therapies [11, 12].
Mannose receptors are highly expressed in cells of the immune system, especially in
professional APCs including DCs and macrophages [13-15]. Transmembrane mannose
receptors mediate endocytosis, function as antigen capture receptors, and are involved in
antigen presentation [16, 17]. The preferential expression of mannose receptors in cells of
the immune system makes them promising targets for various therapies, including
macrophage-targeted chemotherapy and DC-targeted vaccines [18]. Mannose has been
successfully applied to gene delivery to APCs and development of therapeutic vaccines,
and some of them are currently undergoing clinical trials [19].
In this study, we constructed mannosed liposomes (Man-lipo), as APC-targeted carriers
for IDO siRNA (siIDO) delivery. We show that Man-lipo-siIDO can efficiently and
preferentially silence IDO expression in DCs in vitro and in vivo; and that treatment with
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Man-lipo-siIDO inhibited formation of melanoma tumour xenografts in recipient mice,
restrained melanoma tumor xenograft growth, and enhanced anti-tumor immunity in
xenograft host mice.

3.3

3.3.1

Materials and Methods

Chemicals

1,3-Dioleoyl-3-trimethylammonium propane (DOTAP), cholesterol, 1,2-distearoyl-snglycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000] (DSPEPEG2000- carboxylic acid) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N[methoxy (polyethylene glycol)-2000] (DSPE-PEG2000) were purchased from Avanti
Lipids, Inc. (Alabaster, AL). D-(+)-mannose and protamine sulfate were purchased from
Sigma-Aldrich Canada, Ltd. (Ontario，Canada). All other chemicals were reagent grade.

3.3.2

Mice

C57BL/6 mice (6-8 weeks old males) were purchased from The Jackson Laboratory (Bar
Harbor, ME) and maintained under pathogen-free conditions in the Western University
barrier rodent facility. All experiments were performed in accordance with guidelines and
standard operating procedures set out by the Canadian Council on Animal Care and the
Western University Animal Use Subcommittee.

3.3.3

IDO siRNA design

A 21 nt, double-stranded siRNA targeting murine IDO, as described in our previous
report [20] and synthesized by Dharmacon, Inc. (Lafayette, CO, USA). The sequences
were: IDO sequence: sense, 5’-GGGCUUCUUCCUCGUCUCUTT-3’; antisense, 5’-

106
AGAGAC GAGGAAGAAGCCCTT-3’. The sequence for scrambled siRNA was: sense,
5’-CGUACGCGGAAUACUUCGA-3’; antisense, 5’-CGTACGCGGAATACTTCGA-3’.

3.3.4

Cell culture

Bone marrow-derived DCs were generated as previously described [21]. Briefly, bone
marrow cells were flushed from the femurs, washed in ice-cold PBS, and cultured in 12well tissue culture plates (Corning, MA, USA; 2 X 106 seeded cells/well). Each well
contained 2 ml of RPMI1640 medium (Invitrogen Life Technologies, CA, USA)
supplemented with 10% FBS (Invitrogen Life Technologies) and penicillin (100 U/ml),
streptomycin (100 μg/ml), 2-ME (50 μM; Invitrogen Life Technologies), recombinant
murine GM-CSF (10 ng/ml; PeproTech, Quebec, Canada), and IL-4 (10 ng/ml;
PeproTech). Non-adherent cells were removed after 48 h of culture, and medium was
changed after every 48 h of culture. DCs were used for in vitro experiments after 7 days.
B16-F10 mouse melanoma tumor cells were purchased from the American Type Culture
Collection (ATCC, VA, USA) and grown and maintained in RPMI1640 tissue culture
medium supplemented with 10% FBS.
B16F10 murine melanoma cells were cultured in 75-mm culture dishes in Gibco’s
minimal essential medium (DMEM) supplemented with 10% fetal bovine serum (FBS;
Burlington, ON, CA) and antibiotics (100 U/ml of penicillin and 100 lg/ml of
streptomycin).

3.3.5

Synthesis of DSPE-PEG2000-mannose lipid

DSPE-PEG2000-amine (0.12 mmol) was lyophilized, dissolved in DMSO (2 mL), and
mixed with mannose (1 mg) at 25o C for 16 h. The reaction mixture was then evaporated
in a vacuum and the resulting dried material resuspended in water. The water suspension
was dialyzed against distilled water for 48 h using a 3 kDa cut-off membrane (Spectrum,
TX, USA). After the dialysis, the water suspension of DSPE-PEG2000-mannose was filtercentrifuged using Amicon Ultra-15 centrifugal filter units with a 3 kDa MW cut-off
(Millipore, MA, USA). The resulting suspension was lyophilized.
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3.3.6

Preparation of Man-lipo-siIDO

DOTAP, DPPC, cholesterols, and mannose-DSPE-PEG were mixed (3:10:10:4 molar
ratio) to construct a mannose receptor-targeting liposome. The same reagents without the
addition of mannose were used to construct the control, non-mannosed liposome. The
lipids were dissolved in chloroform in a glass tube and evaporated to complete dryness
under vacuum. The lipid film was hydrated by siRNA and protamine mixture. siRNA
(targeting IDO in distilled water was added to an equal volume of liposomes and
protamine at a ratio of 600 nmol DOTAP:30 μg protamine:50 μg siRNA and incubated at
room temperature for 10 min to form multilamellar liposomes and siRNA mixture. The
multilamellar liposome and siRNA mixture suspension was vortexed for 5 min followed
by sonication for 2 min at 50°C in a bath sonicator, and the sonicated suspension was
extruded sequentially through polycarbonate membranes of decreasing pore size (0.4, 0.2
and 0.1 mm diameter pores). Finally, a post-insert technique [22] was used to construct
non-mannosed and mannosed liposomes. The liposome nanoparticle solution was
incubated (50°C, 10 min; followed by cooling to 25oC) with DSPE-PEG2000 or
mannose-DSPE-PEG2000 to generate non-mannosed and mannosed liposomes,
respectively.

3.3.7

Mannosed liposome particle diameter and zeta potential

Freshly prepared non-mannosed and mannosed liposomes were diluted with phosphatebuffered saline (PBS) and the mean particle diameter and surface charge (zeta potential)
measured using a Zetasizer Nano Series (Malvern Instruments Ltd., UK) according to the
manufacturer's protocol.
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3.3.8

In vitro uptake of liposomes loaded with Cy3 siRNA (Manlipo-Cy3 siRNA)

Mouse dendritic cells were cultured for 6 days and then transfected with Man-lipo-Cy3
siRNA, non-mannosed-lipo-Cy3 siRNA, empty Man-lipo, empty non-mannosed-lipo, or
naked Cy3 siRNA. Cells were harvested 4 h after transfection and Cy3 fluoresence
visualized by fluorescent microscopy. Untransfected DCs and DCs transfected with Manlipo-Cy3 siRNA or non-mannosed-lipo-Cy3 siRNA were similarly collected 4 h posttransfection and analyzed for Cy3 siRNA uptake by flow cytometry.

3.3.9

In vitro silencing of IDO in DCs using Man-lipo-siIDO

Mouse DCs were cultured for 6 days and then transfected with Man-lipo-siIDO.
Mannosed liposomes loaded with control siRNA (non-complementary to any known
mouse RNA; Man-lipo-siScramble) were used as negative controls. Total cellular RNA
was isolated from DCs 24 h after transfection for quantitative PCR analysis.

3.3.10

In vivo distribution of Man-lipo-Cy3-siRNA

Non-mannosed-lipo-Cy3 siRNA or Man-lipo-Cy3 siRNA were injected intravenously
into mouse tail veins (50 μg/mouse). Mice were euthanized 6 h post-injection and organs
(heart, liver, spleen, lung and kidney) collected, rinsed with saline, snap-frozen in liquid
nitrogen, mounted for cryostat sectioning, and viewed using fluorescent microscopy.

3.3.11

In vivo silencing of IDO using Man-lipo-siIDO

Man-lipo-siIDO and Man-lipo-siScramble were injected intravenously into mouse tail
veins (50 μg/mouse). Mice were euthanized 24 h later and splenocytes and lymphocytes
were collected for RNA isolation. All RNAs were prepared for quantitative PCR analysis.
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Man-lipo-siIDO and Man-lipo-siScramble were injected intravenously into mouse tail
veins (50 μg/mouse). Mice were euthanized 24 h later and splenocytes and lymphocytes
were collected and CD11C+ DCs were isolated using CD11C mouse Microbeads
(Miltenyi Biotec, Auburn, CA) for RNA isolation. All RNAs were prepared for
quantitative PCR analysis.

3.3.12

Quantitative PCR analysis of IDO mRNA

After in vivo treatment of mice or in vitro treatment of DCs with liposomes loaded with
control or IDO siRNA, total cellular or tissue RNA was isolated using Trizol (Invitrogen)
and then used as a template for cDNA synthesis and quantitative PCR (qPCR). qPCR
reactions were carried out using gene-specific forward and reverse primers (100 nM each)
and SYBR Green PCR Master mix (Stratagene, La Jolla, CA,) in a Stratagene MX 4000
Multiplex qPCR System. Primers used for the amplification of murine IDO and GAPDH
were: IDO, 5’-GAAGGATCCTTGAAGACCAC-3’ (forward) and 5’GAAGCTGCGATTTCCACCAA-3’(reverse); GAPDH, 5’TGATGACATCAAGAAGGTGGTGAA-3’ (forward) and 5’ TGGGATGGAAATTGTGAGGGAGAT-3’ (reverse).

3.3.13

Effect of Man-lipo-siIDO on in vivo mouse melanoma tumor
growth

B16-F10 mouse melanoma cells (2 x 105 cells) were suspended in 20 μl of PBS and
injected s.c. and dorsally into each C57BL/6 mouse. Man-lipo-siIDO or control
liposomes encapsulating 100ug siRNA in a volume of 300ul were injected i.v. into mice
2 days prior to injection with tumor cells and once per week thereafter. Control mice
were identically injected with tumor cells followed, at the same time as injection of mice
with Man-lipo-siIDO, injection with vehicle control, Man-lipo-siScrambled, or nonmannosed-lipo-siIDO. Mice were checked for tumor formation on alternate days. The
day of tumor appearance was noted and thereafter each tumor was measured by caliper
and volumes estimated using the following formula: tumor volume = 0.5 x (width2) x
(length).
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3.3.14

Flow cytometry

Estimation of Cy3 siRNA incorporation by freshly-isolated and cultured DCs was
performed by flow cytometry (BD Biosciences, CA). All monoclonal antibodies (mAbs)
were from BD Pharmingen, NJ). T cell subsets were analyzed by staining with PEconjugated or Cy5-conjugated CD4 mAbs, Cy5-conjugated CD8 or CD25 mAbs, and
FITC-conjugated FoxP3 antibodies. Apoptosis of T cells was determined by staining with
the above mAbs, FITC-conjugated annexinV and Propidium iodide (PI). All flow
cytometric analyses were performed using appropriate isotype controls.

3.3.15

Tumor antigen response

Mice were euthanized 28 days after tumor inoculation, T cell suspensions prepared from
spleens and lymph nodes [23]. Spleenocytes from melanoma bearing mice were isolated
by gradient centrifugation over Ficoll-Paque (Amersham Pharmacia Biotech, Montreal,
Quebec, Canada) and cultured in 96-well plates (4x105 seeded cells/well) in the presence
or absence of B16-F10 tumor Ag in a gradient concentration of 5ug/ml, 25 μg/ml and 50
μg/ml for 72h. Tumor antigens were prepared as previous description [24]. Briefly, B16F10 cells were trypsinized and resuspended at a density of 5x106/ml in serium frees
RPMI. Then the suspension was freeze-thawed by -80oC and 4°C cycles for at least 5
times. The protein (from both cell cytoplasma and cell membrane) concentration of the
lysate was determined by a commercial assay (Bio-Rad, Munich, Germany).The mixed
lymphocytes and Ag were cultured at 37°C for 72 h in 200 μl of RPMI 1640
supplemented with 10% FBS, 100 U/ml of penicillin, and 100 μg/ml of streptomycin and
pulsed with 1 μCi/well of 3H-labelled thymidine (Amersham Pharmacia Biotech) for the
last 18 h of culture. Results were expressed as mean counts per minute of triplicate
cultures ± SEM.

3.3.16

Statistical analysis

Data are presented as means ± SD. Control and experimental data were compared using
one-way ANOVA followed by Newman-Keuls testing. p-values less than 0.05 were
assumed a priori to indicate significant differences.
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3.4

3.4.1

Results

Preparation and characterization of Man-lipo-siRNA

The size and surface charge of liposomes are of vital importance to transfection
efficiency and biodistribution [25]. Small size avoids preferential uptake by Kupffer and
other reticuloendothelial cells, and a slight positive charge facilitates association with
negatively-charged RNA and target cell plasma membrane components [26, 27]. To
estimate whether Man-lipo-siRNAs prepared by us had the appropriate size and surface
charge for effective in vivo delivery, we measured final liposomal particle diameter and
zeta potential (Fig. 3-1, A and B). Particle size was approximately 180 nm (Fig.3-1A) and
surface charge of Man-lipo-siRNA (represented by zeta potential) was slightly positive
and approximately 20 mV (Fig. 3-1B). The Man-lipo and the Non-man-lipo has a similar
size and zeta potential. The addition of mannose does not influence the size and zeta
potential of the liposome. These data suggest that, according to previously described
parameters, the size and surface charge of the prepared liposomes were suitable for
potential in vivo siRNA delivery [28]. This experiment was repeated three times. In each
experiment, over 300 liposome particles were tested.
To determine whether IDO siRNA was encapsulated inside the liposome and protected
from RNase degradation, the stability of liposomal siRNA was assessed. Fresh mouse
plasma was mixed with Man-lipo-siIDO, non-mannosed-lipo-siIDO, or naked siIDO.
Compared to naked siIDO, siIDO encapsulated within mannosed liposomes or nonmannosed-liposomes were protected for at least 48 h (Fig. 3-1C) suggesting that
liposomes provide protection against systemic degradation of siRNA by nucleophiles and
nucleolytic enzymes, and that addition of mannose to liposomes does not diminish that
protective capacity.
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Figure 3-1 Preparation and characterization of Man-lipo-siRNA. (A & B) Determination
of the size and zeta potential of Man-lipo-siRNA and non-mannosed-lipo-siRNA. Manlipo-siRNA or non-mannosed-lipo-siRNA were prepare as described in materials and
methods. The size (A) and the zeta potencial (B) of Man-lipo-siRNA and non-mannosedlipo-siRNA were measured by zetasizer. (C) Serum protection assay. Naked siRNA,
Man-lipo-siRNA, or non-mannosed-lipo-siRNA were incubated with fresh mouse plasma
at 37 oC at various time points. 1, 4, 8, 24 and 48 h post incubation, liposomes that
encapsulated siRNA were lysised by Tris-Triton 100. siRNA was visualized by agarose
electrophoresis. The data shows the compiled data from all three experiments.
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3.4.2

In vitro targeting by Man-lipo-Cy3 siRNA and gene silencing
of IDO

DCs express mannose receptors [16] and are among the most important antigenpresenting cells in vivo. To evaluate the targeting efficiency of Man-lipo-Cy3 siRNA to
mannose receptor, DCs isolated from mouse bone marrow and cultured in vitro for 6 days
were used to assess capacity of Man-lipo-Cy3 siRNA to deliver siIDO and reduce IDO
mRNA levels. Compared to non-mannosed-lipo-Cy3 siRNA, Man-lipo-Cy3 siRNA has a
significantly higher targeting efficiency and cellular uptake (Fig. 3-2, A and B).
To determine the silencing efficiency of the Man-lipo-siIDO in vitro, Man-lipo-siIDO
was used to deliver IDO siRNA to identically-prepared DCs in vitro. Compared to Manlipo-siScrambled, Man-lipo-siIDO significantly reduced the level of IDO mRNA (Fig. 32C). The differences of IDO expression between the Non treatment control and Manlipo-siScrambled are not significant. This data demonstrates that Man-lipo-siIDO is
capable of delivering siRNA to DCs and to reduce IDO expression.

3.4.3

Bio-distribution of Man-lipo-Cy3-siRNA and in vivo IDO gene
silencing

To test targeting efficacy of Man-lipo-siRNA in vivo, we investigated the biodistribution
of Man-lipo-Cy3 siRNA in mice. Man-lipo-Cy3 siRNA or non-mannosed-lipo-Cy3
siRNA was injected into mice and the distribution of Cy3 siRNA (red fluorescent signal)
to heart, liver, spleen, lung and kidney were compared between the two and with organs
from mice untreated with liposomes (Fig. 3-3A). Compared to non-mannosed-lipo-Cy3
siRNA controls or non-treatment controls, Man-lipo-Cy3 siRNA accumulated to a
significantly higher in lymph node, spleen and liver, consistent with the reported location
of mannose receptors in normal, non-tumor mouse tissue [19]. The fluorescence that
represents the distribution of Man-lipo-Cy3 siRNA is consistant over 24 h and 48 h (data
not shown), but the intensity of fluorescence is weaker as time goes by. Therefore, 6 h
bio-distribution was chosen. This data indicates that Man-lipo-siRNA can preferentially
target mannose
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Figure 3-2 In vitro targeting assay of Man-lipo-Cy3-siRNA and gene silencing of IDO.
(A) Transfecting DCs with Man-lipo-Cy3-siRNA. Six-day-cultured DCs were transfected
with Man-lipo-Cy3-siRNA (k, l) and non-mannosed-lipo-Cy3-siRNA (i,j). Non treatment
DCs (a,b), DCs treated with empty Man-lipo (c,d) or empty non-mannosed-lipo (e,f) and
DCs treated with naked Cy3 labeled siRNA (g,h) served as controls. The red fluorescence
of Cy3 was detected by fluorescent microscope 4h post transfection. The magnification is
10x. (B) Transfection efficacy of Man-lipo-Cy3-siRNA detected by flow cytometry. Sixday-cultured DCs were transfected by Man-lipo-Cy3-siRNA and non-mannosed-lipoCy3-siRNA. 4 h after transfection, the cells were harvested and the fluorescence of
encapsulated Cy3-labeled siRNA was detected by flow cytometry. Experiment were
repeated three times. (C) Gene silencing of IDO using Man-lipo-siIDO. Six-day-cultured
DCs were transfected by Man-lipo-siIDO and non-mannosed-lipo-siIDO. 24 h after
transfection, DCs were harvested and message RNA was isolated. The IDO expression of
DCs was detected by real time PCR. *p<0.05.
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Figure 3-3 Bio-distribution of Man-lipo-Cy3-siRNA. (A) Bio-distribution of Man-liposiRNA. Mice were i.v injected with Man-lipo-Cy3-siRNA and non-mannosed-lipo-Cy3siRNA. 6 h post administration, mice were sacrificed and lymph node, spleen, liver, heart,
kidney, lung were extracted for frozen sections. The red fluorescence of Cy3-labeled
siRNA in the various tissue sections was observed under fluorescent microscope. The
data presented one of three independent experiments. The magnification is 10x.
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receptor- expressing tissues and efficiently deliver siRNA into liver and important
immune organs such as spleen and lymph node.
In order to assess in vivo gene silencing efficacy in addition to siRNA delivery, Manlipo-siIDO was injected i.v. into mice. Expression of the IDO gene in lymph node and
spleen was significantly reduced compared to organs in animals treated with Man-liposiScrambled control (Fig. 3-4 A&B).
To further confirm that DCs in vivo have been targeted and the IDO expression in DCs
has been knocked down, 24 hours post administration, CD11C+ cells of non-treatment
mice, mice injected with Man-lipo-siScramble and Man-lipo-siIDO were isolated from
splenocytes and lymphocytes of Balb/C mice. Total RNA was isolated from the CD11C+
cells in different experiment groups and the IDO expression was determined by qPCR.
The IDO expression in Man-lipo-siIDO treatment group was significantly decreased
when compare to Man-lipo-siScramble, and no significantly different could be found
between non treatment control and Man-lipo-siScramble treatment (Fig. 3-4 C).

3.4.4

Therapeutic effects of Man-lipo-siIDO

It has been reported that more aggressive tumor grow is observed in the cancer patients
with more IDO+ DC expression in DCs [9]. In order to determine whether knock down of
IDO may restrain the tumor growth, we treated melanoma-bearing mice with Man-liposiIDO. As shown in Fig. 3-5 A&B&C, compare to non-mannosed-lipo-siIDO, Man-liposiScrambled control and non-treatment control, melanoma bearing mice that were
injected with Man-lipo-siIDO has lengthened time between tumor cell inoculation and
the appearance of palpable tumors; reduced tumor size at equal times after tumor cell
inoculation; lower tumor weight (28 days after tumor inoculation). The tumor weight is
different between the Man-lipo-siIDO and non-mannosed-lipo-siIDO treatment groups
when compared to tumor size. Compared to melanoma in early stage, advanced
melanoma contains more liquid inside the tumor since advanced vascularization is
formed. The early stage melanoma contains more connective tissue,
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Figure 3-4 In vivo gene silencing of IDO. (A & B) In vivo gene silencing by Man-liposiIDO. Man-lipo-siIDO or Man-lipo-siScrambled were i.v injected into melanoma
bearing C57/BL6 mice. 24 h after injection, mice were sacrificed and the IDO expression
in spleen (A) and lymph node (B) were detected by real time qPCR.*p<0.05. (C) In vivo
silencing of IDO on CD11C+ DCs by Man-lipo-siIDO. Man-lipo-siIDO or Man-liposiScrambled were i.v injected into C57/BL6 mice. 24 h after injection, mice were
sacrificed and CD11C+ DCs were isolated for IDO expression determination. IDO
expression was detected by qPCR. *p<0.05. The data presented complied results from 3
experiments. 24 mice were randomly distributed in each group in each experiment.
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Figure 3-5 Anti-tumor effects of Man-lipo-siIDO. (A & B) Experimental treatment of
murine melanoma using Man-lipo-siIDO. Man-lipo-siIDO, or non-mannosed-lipo-siIDO,
or Man-lipo-siScramble was i.v. injected into C57/BL6 mice two days before tumor
inoculation. Treatments were repeated once a week thereafter. Tumor size (A) in
treatment and control mice was monitored every three days. Onset time (B) in treatment
and control mice was monitored every day after tumor inoculation. (C) Tumours in
different experimental groups or control groups were extracted and weighted in day 28
after mice were sacrificed. Results represent compiled data from all three experiments.
Each point represents the weight of 6 mice in each group. Results represent 1 of 3
experiments.*p<0.05 (Man-lipo-siIDO vs non-mannosed-lipo-siIDO)
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which usually located between the malignant tissue and normal tissue, includes skin and
muscle. Since the size measurement includes the connective tissue but the weight
measurement does not include the connective tissue, which may explain the inconsistence
between the tumor size and tumor weight measurement.
Accumulation of IDO+ DC in lymph node correlates the poor prognosis of cancers by
inducing CD4+ and CD8+ T cells apoptosis, which subsequently leads to the slowing of
tumor growth [6, 9, 29]. In order to identify that silencing IDO expression in spleen and
lymph node can reduce CD4+ and CD8+ T cell apoptosis, splencoytes and lymphocytes
isolated by Ficoll were stained with Cy5-conjugated CD4 mAbs, Cy5-conjugated CD8,
FITC-conjugated annexin V and PI were detected by flow cytometer. Dead cells were
excluded by PI staining in analysis. Compare various control groups, the CD4+ and CD8+
apoptosis T cells population in drain lymph node, lymph node and spleen were
significantly less in Man-lipo-siIDO injected mice (Fig. 3-6 A-F). When compared to
Man-lipo-siScramble, non-mannosed-lipo-siIDO has significantly less apoptosis CD4+
cells in draining lymph node and spleen, also less apoptosis CD8+ T cells in non-draining
lymph node and spleen. However, the apoptosis was further reduced by the addition of
mannose into the delivery system. This suggests that Man-lipo-siIDO arouses anti-tumor
effects might partially attribute to the reducing CD4+ and CD8+ T cell apoptosis
population in spleen, lymph node and draining lymph node.

3.4.5

Enhancement of anti-tumor immunity by Man-lipo-siIDO

The expression of IDO induced tumor escape is mainly caused by the IDO induced T cell
apoptosis and immune suppression[7]. Thus, we detected the anti-tumor immunity by
evaluating the anti-tumor antigen ability of the splenocyte and lymphocyte. When
compare to Man-lipo-siScramble and Non-treatment control, non-mannosed-lipo-siIDO
treatment mice has relatively stronger reaction against to the B16-F10 melanoma antigen.
The differences between Non-treatment control, Man-lipo-siScramble and nonmannosed-lipo-siIDO are not statistically significant. Mice treated with Man-lipo-siIDO
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Figure 3-6 Suppression of T cells apoptosis by Man-lipo-siIDO. C57/BL6 mice were
treated with Man-lipo-siIDO, or non-mannosed-lipo-siIDO, or Man-lipo-siScramble, as
described in the legend to Fig. 4. The mice were sacrificed in day 28, and the CD4+ and
CD8+T cells in drain lymph node (A, B), lymph node (C, D) and spleen(E, F) were
isolated. The apoptosis in CD4+ and CD8+ T cells were detected by flow cytometry after
Annexin V staining. Results represent complied results from 3 experiments (n = 6 per
group/experiment). *p<0.05.
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have significantly stronger response against to tumor antigen when compared to mice
treated with non-mannosed-lipo-siIDO (Fig. 3-7 A&B).
Recent evidence suggests that IDO promotes the generation of induced Tregs[30].
Clinical studies reveal that there is a positive correlation between the levels of IDO
induced Tregs and poor clinical outcomes [31]. We speculated that by down regulation of
IDO expression, the expression of Tregs in spleen, especially in drain lymph node will be
decreased. As shown in Fig.3-7 C&D, mice injected with Man-lipo-siIDO had lower
Treg expression when compare to non-treatment control and Man-lipo-siScrambled
control. These results highlight that the Man-lipo-siIDO was able to inhibit Treg cells and
enhance the overall anti-tumor immunity of T cells.

3.5

Discussion

Increasingly accumulating data from clinical and basic research demonstrates that IDO
plays an important role in tumor immune evasion[32]. The tumor escape induced by IDO
is mostly attributed to IDO+ DC induced T cell apoptosis and Treg accumulation [9, 33,
34], which leads to the immune dysfunction of the immune organ, especially the sentinel
lymph node [35, 36]. However, effective therapy by knocking down the expression of
IDO through specifically targeting APCs in lymph node and spleen has not yet been
reported. In this study, we developed a APC-targeting delivery system based on specific
affinity of mannosed-liposome to mannose receptor expressing APCs. We observed that
Man-lipo-siIDO can efficiently target DCs and repress IDO expression on DCs in vitro
and in vivo. By silencing IDO expression in spleen and lymph node of tumor bearing
mice, tumor growth could be restricted, which might attribute to the significantly
decreased of Treg cells populations as well as significantly decreased apoptotic CD4+ and
CD8+ effector T cells in the draining lymph node and spleen.
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Figure 3-7 Manipulation of anti-tumor immunity by Man-lipo-siIDO. (A & B) TumorAg-specific T cell response. T cells isolated from lymph node (A) and spleen (B) of
various experimental and control groups were mixed with indicated concentration of
tumor antigen respectively. Cells were pulsed with 1 μCi of [3H] thymidine for the last 18
h. T cells proliferation level was determined by radioactivity detection. Results were
expressed as the mean counts per min of triplicate cultures ± SEM (n = 6 per
group/experiment) *= p<0.05 (Man-lipo-siIDO vs non-mannosed-lipo-siIDO). (C&D)
Treg cells in Man-lipo-siIDO treated tumor-bearing mice. C57/BL6 mice were treated
with Man-lipo-siIDO, or non-mannosed-lipo-siIDO, or Man-lipo-siScramble, as
described in the legend to Fig. 4. After mice were sacrificed, CD4+ T cells from drain
lymph node (C) and spleen (D) were isolated. CD4+CD25+FoxP3+ Treg cells were
detected by flow cytometry. Results represent 1 of 3 experiments (n = 6 per
group/experiment). *p<0.05.
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RNAi is an endogenous mechanism in which double-stranded RNA knocks down the
expression of homologous genes, thus induces gene silencing. Since it was first observed
in late 1980, it had been used as a powerful laboratory technique for gene silencing [10].
Recently, some research on animal disease model, such as cancer, viral infection, and
age-related macular degernation has moved RNAi forward in clinical application.
However, the lack of specific and effective in vivo delivery methods is the major barrier
for its application [11, 12]. While “flooding” the system with siRNA in the form of
hydrodynamic administration is effective in animal models, this approach is not practical
for clinical intervention [37]. The ability to selectively deliver siRNA to specific cells
would allow for lower concentrations of siRNA to be used, as well as possibly the
alleviating need for systemic delivery. We have been developed several tissue/cellspecific targeting methods for siRNA delivery [38, 39]
Comparing liposomes with other carrier delivery systems, liposomes offer multiple
advantages for drug delivery, including their biocompatibility, biodegradability and
safety. Mannosed liposomes have been considered as promising non-live vectors for
targeted delivery purposes [40]. In order to achieve DCs-targeted delivery of IDO siRNA,
we conjugated D-(+)-mannose to the liposome, which specifically binds to the Lectins
expressed in mice/humans that have shown mannose-binding activity include
transmembrane proteins such as the classical Macrophage mannose receptor (MMR
group VI), Endo180, dendritic cell-specific intercellular adhesion molecule-3 grabbing
non-integrin (DC-SIGN), DC-SIGN related (L-SIGN, group II, type 2 receptors) or their
mouse homologues (SIGNR), Langerin or secreted/soluble proteins such as the collectins
mannose binding protein (MBP), surfactant protein A and surfactant protein D (group III)
[19].
Mannosed particulates are formed by the association of the mannose derivative to a
carrier (liposome, nanoparticle, etc.). The mannose derivative acts as a targeting agent
whereas the particulate or carrier acts as a reservoir for the therapeutic agent. Because of
their particulate nature, these particles will be engulfed by phagocytic APCs and
mannosylation will further improve their phagocytosis mediated by specific receptors.
Transmembrane mannose receptors mediate endocytosis, function as antigen capture
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receptors and are involved in antigen capture and presentation[17, 41]. After recognition,
MMR delivers the antigen to the early endosomes and recycles to the surface [42]. The
content of endosomes is subsequently targeted to lysosomes in which the degradation
produces antigen fragments that, after presentation in MHC molecules, can stimulate the
adaptive immune responses[41]. For DC-SIGN, this receptor delivers the bound
components to late endosomes or lysosomes where they are degraded. The generated
antigens are processed for MHC class II presentation to T cells [43]. Under specific
conditions, both MMR and DC-SIGN appear to deliver the antigens in MHC class I
molecules [44, 45]. Mannosed liposome has been used in various vaccine studies
targeting DCs in vivo. For example, the peptide-based mannosed lipoarabinomannan
(ManLAM) is reported to be able to target the host DCs and arouse antibodies against
Mycobacterium tuberculosis [46]. In our study, we observed a strong targeting ability of
our Man-lipo-siRNA towards DCs. Further, We also observed that the Man-lipo-siIDO
can efficiently target macrophage in vivo, which is also an important antigen presenting
cell that influence T cell proliferation [5]. When compared to non-mannosed-lipo-siIDO,
which could only deliver siRNA into 15% of CD11b+ cells in splenocytes and
lymphocytes, the Man-lipo-siIDO could transfected up to 70% of CD11b+ cells in
splenocytes and lymphocytes. The IDO expression can be significantly knocked down in
macrophage (data not shown). In our study, although a much less targeting efficiency in
Non-mannosed-lipo-siIDO groups when compared to Man-lipo-siIDO groups is observed,
the restriction of tumor growth, reduction apoptotic CD4+ and CD8+ T cells and the upregulation of antigen response is significant. It could attribute to the characteristic of the
liposomes; they would finally be engulfed by APCs when circulate in the circulation
system. By being engulfed by the APCs, they silenced the IDO expression and exerted
the anti-tumor effect. However, compared to non-mannosed-lipo-siRNA, the Man-liposiRNA locates much more in spleen and lymph node and less located in liver. This result
demonstrates that the addition of mannose to the liposome can enhance the cellular
uptake of siRNA by guiding the whole lipoplex to organs that are rich of APCs and
significantly increased the anti-tumor ability.
DCs and macrophages are the most important APCs, which are closely related to cancer
immunity and clinical outcome. Accumulating reports have extended on the immune-

132
repressive role of IDO in cancer diseases [47]. IDO+ DCs in humans often show a
morphology of plasmacytoid and express CD123 and CCR6 chemokine receptor
simultaneously [48, 49]. It is possible that IDO expression of IDO in these cells was
stimulated by Toll-like receptor (TLR)-9 ligands activation, and them facilitates the
generation of adaptive Treg cells from naïve allogeneic CD4+CD25- T cells [7]. In mice,
the IDO+ DCs occupies a proximally 0.3-0.5% of total lymph node cells, these cells
accumulates in tumor-draining lymph nodes can results in local T cell repression[9]. In
our study, we observed a significantly decreased apoptosis of CD4+ and CD8+ T cell in
Man-lipo-siIDO groups, which demonstrates that by specifically silencing IDO, local T
cell can be protected from apoptosis. We also successfully reduced the Treg population in
both tumor draining lymph nodes and spleen, which plays an important role in limiting
tumor growth and metastasis [50]. The splenocytes and lymphocytes are reinstalled with
anti-tumor ability through our therapy, when compare to other controls, such as nonmannosed-lipo-siIDO control, Man-lipo-siScrambled control and non-treatment control,
Man-lipo-siIDO treated mice has significantly anti-tumor immunity, which further
demonstrates that our therapy is preferentially targeting and potent.
In summary, we report here a mannose expressing APCs targeting systems to delivery
IDO siRNA can efficiently block the IDO expression in splenocytes and lymphocytes.
Treatment of Man-lipo-siIDO results in significantly lengthened tumor onset time,
reduced tumor size and tumor weight; decreased apoptosis of CD8+ and CD4+ T cells
isolated from spleen and lymph nodes; increased reactivity of T cells isolated from spleen
and lymphe nodes against B16 melanoma cell antigens and decreased
CD4+CD25+FoxP3+ Treg cells isolated from spleen and draining lymph nodes.
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Chapter 4

4

Targeted siRNA silencing of BRAF in melanoma
using folate receptor-conjugated liposomes

4.1 Summary
The high frequency of mutation (60-80%) in melanoma and its central role in regulation
of cell proliferation and survival makes v-Raf murine sarcoma viral oncogene homolog
B1 (BRAF) a heat key target for melanoma therapy. However, the off target and drug
resistance effects create many difficulties in practical use. Targeting gene silencing by
siRNA could be a promising alternative, since it is highly specific to the mRNA sequence
of the intended gene. B16-F10 murine melanoma cell line retains high levels of BRAF
expression while consistently expressing folate receptor. In this study, we constructed a
liposomal folate receptors targeting siRNA delivery system. The B16-F10 targeting
efficiency of folate liposome encapsulated siRNA (Folate-lipo-siRNA) was detected by
flow cytometry in vitro and fluorescent microscopy in vivo. Cells that were transfected
with BRAF siRNA had significantly less proliferation in vitro. In a mouse melanoma
model, compared to controls (Non-treatment mice, mice treated with Folate-liposiScramble, or with non-folate-lipo-siBRAF), mice treated with Folate-lipo-siBRAF had
a reduced tumor volume, tumor weight and reduced expression of PCNA and vascular
networks in tumor tissue. This study demonstrates that using Folate-lipo-siBRAF can
preferentially silence BRAF expression in folate receptor expression cells in vitro and in
vivo and that silencing BRAF by siRNA can prevent melanoma growth. This study
highlights that Folate-lipo-siBRAF has potential for development as an anticancer
therapeutic agent.

4.2

Introduction

Melanoma is the sixth most common cancer and the malignancy with the highest
continuing rise in incidence [1]. For several decades the progress in the melanoma field is
slow. Systemic therapies have made little or no contribution to overall survival rate [2-4].
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However, the identification of mutant BRAF, which is now known to be a major driver of
melanoma progression, provided great progress in treatment of melanoma [5].
RAF is the first identified RAS downstream effectors. The RAF family is composed of
three members, A-RAF, B-RAF and RAF1 (or C-RAF), within which, B-RAF is
considerably stronger in kinase activity than the other two isotypes [6, 7]. B-RAF is
serine threonine kinase, which is part of the RAF/MEK/ERK serine threonine kinase
cascade. This cascade , also called ‘classical’ MAPK pathway, regulates cell growth,
survival and differentiation [8].The discovery of oncogenic BRAF mutations in
melanoma was in 2002, since then, B-RAF stands as one of the most powerful
affirmations of the transformative potential of systemic cancer genome characterization
[7, 9]. Recently, B-RAF mutations have been reported at high frequencies of over 70% in
melanoma [10]. The mutations are also found in premalignant atypical or dysplastic nevi,
which suggest that B-RAF activation could be an initiating event in tumorigenesis[11,
12]. Lots of B-RAF inhibitors have emerged and been tested in clinical trials. However,
resistance is found in the later or follow-up treatment on patients. siRNA therapy could
be a potential alternative since siRNA can knock down the expression of any proteins or
non-coding RNAs and can be easily synthesized or cloned into expression vectors
(shRNA) with minimal toxicity. In contrast, chemical inhibitors against certain proteins
are limited and constructing dominant negative mutants is time-consuming. Moreover,
the chemical inhibitors and dominant negative mutants are more toxic to the cells
compared with siRNAs [13].
Folic acid is a water-soluble B vitamin, which is essential for de novo synthesis and one
carbon transfer reactions[14].Folate receptors (FRs), also known as folate-binding
proteins (FBP), are N -glycosylated proteins with high binding affinity to folate in vivo.
FRs include at least four isoforms, α ,  ,  / γ ′and δ.The affinities of folic acid for the
FRs are: FR- α , Kd~ 0.1 nM[15]; FR- β , Kd ~1 nM[16]; and FR- γ , Kd ~ 0.4 nM[17].
Functional FR expression is low or absent in most normal tissues, only FR- α expression
in the luminal surface of certain epithelial cells [18], which are inaccessible to blood
circulation. In contrast, many malignant cancers, especially epithelial carcinomas,
consistently and uniformly express high levels of FR-, which is accessible to blood
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circulation[14, 19].The frequent overexpression within tumors and highly restricted
distribution in normal tissues suggest that both FR- and - can potentially be exploited
as a tumor-specific cell surface marker that can be used in the targeted delivery of cancer
therapeutics[14, 20]. Since B16-F10 melanoma over-express B-RAF while consistently
expressing folate receptors [21], this makes it an ideal modal for investigating the
potential therapeutic application of Folate-lipo-siBRAF.
In this study, we constructed a liposomal folate receptors targeting siRNA delivery
system which can preferentially knock down B-RAF in B16-F10 cells in vitro.
Administration of folate receptor targeted liposomes encapsulated B-RAF siRNA
(Folate-lipo-siBRAF) resulted in the knockdown of B-RAF expressing in tumor tissue,
which leads to the reduced proliferation and vascularization of tumor cells in vivo.

4.3

4.3.1

Materials and Methods

Chemicals

1, 3-Dioleoyl-3-trimethylammonium propane (DOTAP), cholesterol, folatedistearoylphosphatidylethanolamine-N-poly(ethyleneglycol) (Folate-DSPE-PEG) and
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)2000] (DSPE-PEG2000) were purchased from Avanti Lipids, Inc. (Alabaster, AL). All
chemicals were reagent grade.

4.3.2

Mice

C57BL/6 mice (6-8 weeks old males) were purchased from The Jackson Laboratory (Bar
Harbor, ME, USA) and maintained under pathogen-free conditions in the Western
University barrier rodent facility. All experiments were performed in accord with
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guidelines and standard operating procedures set out by the Canadian Council on Animal
Care and the Western University Animal Use Subcommittee.

4.3.3

BRAF siRNA design

A double-stranded siRNA targeting murine B-RAF, as described in previous report[22]
and was synthesized by Dharmacon, Inc. (Lafayette, CO, USA). The sequences were: BRAF sequence: sense, 5’-GCUUACUGGAGAGGAGUUACA-3’; antisense, 5’UGUAACUCCUCUCCAGUAAGC-3’. The sequence for scramble siRNA was: sence,
5’-CGUACGCGGAAUACUUCGA-3’; antisense, 5’-CGTACGCGGAATACTTCGA-3’.

4.3.4

Cell culture

B16F10 murine melanoma cells were cultured in 75-mm culture dishes in Gibco’s
minimal essential medium (DMEM) supplemented with 10% fetal bovine serum (FBS;
Burlington, ON, CA) and antibiotics (100 U/ml of penicillin and 100 lg/ml of
streptomycin).

4.3.5

In vitro silencing using siBRAF and evaluation of antiproliferation effect of siBRAF

B16F10 cells were transfected with B-RAF siRNA using L2K (Invitrogen, Carlsbad, CA,
USA). The non-treatment cells were used as negative controls. Briefly, cells were plated
into 24-well plates (1.5×105 cells per well) and allowed to grow overnight, to reach 80%
confluence. Cells were transfected with 0.5μgB-RAF siRNA in serum-reduced medium
for 4 h, and then incubated in complete medium for 24 h. All RNAs were prepared for
quantitative PCR (qPCR) analysis.
24 h post siRNA transfection, B16-F10 cells were re-plated in 96 well/plate in a number
of 500/well. Cells were then subculture for 68 h then (3-(4,5-Dimethylthiazol-2-yl)-2,5-
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diphenyltetrazolium bromide (MTT) was added and co-incubate for 4 h. After coincubation, cells were centrifuged and supernatant was removed and 150μl of DMSO
were added and mixed. Absorbence was read by microplate reader (bench mark
microplate reader, Bio Rad, Mississauga, Ontario, CA) at a wavelength of 695nm as a
reference and 590nm as the absorbance.
24 h post siRNA transfection, B16-F10 cells were re-plated in 96 well/plate in a number
of 500/well. Cells were then subcultured in the indicated time point. 24 h, 48 h, 72 h, 96 h
and 120 h after re-plating, cells were suspended and trypan blue was used for cell
counting.

4.3.6

Western Blot

B16-F10 cells were plated into 24-well plates (1.5×105 cells per well) and allowed to
grow overnight, to reach 80% confluence. Then cells were transfected with siBRAF or
siScramble using lipofectamine for 72 h. Cells were washed and lysised by RIPA buffer
(cells signaling technology, Danvers, USA) and total cellular protein was isolated from
B16-F10 cells 72 h after transfection for western blot analysis using anti-mouse B-RAF
(Abcam, Toronto, ON, CA) antibody.

4.3.7

Preparation of Folate-lipo-siBRAF

DOTAP, DPPC, cholesterols, and Folate-DSPE-PEG were mixed (3.75:13:13:1 molar
ratio) to construct a folate receptor-targeting liposome. DSPE-PEG2000 (molar ratio to
DOTAP was 3.75:4) was added after extrusion. The same reagents without the addition
of folate were used to construct the control, non-folate liposome. The lipids were
dissolved in chloroform in a glass tube, evaporated to complete dryness under vacuum.
The lipid film was hydrated by the siRNA and protamine mixture. siRNA (targeting BRAF in distilled water was added to an equal volume of liposomes and protamine at a
ratio of 600 nmol DOTAP:30 μg protamine:50 μg siRNA and incubated at room
temperature for 10 min to form multilamellar liposomes and siRNA mixture. The
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multilamellar liposome and siRNA mixture suspension was vortexed for 5 min followed
by sonication for 2 min at 50°C in a bath sonicator, and the sonicated suspension
extruded sequentially through polycarbonate membranes of decreasing pore size (0.4, 0.2
and 0.1 mm diameter pores). The liposome nanoparticle solution was incubated (50°C, 10
min; followed by cooling to 25oC) with DSPE-PEG2000 in a molar ratio to DOTAP of
3.75:4 and 3.75: 5 to generate Folate and Non-folate liposomes, respectively.

4.3.8

Folate liposome particle diameter and zeta potential

Freshly prepared Non-folate and Folate liposomes were diluted with phosphate-buffered
saline (PBS) and the mean particle diameter and surface charge (zeta potential) measured
using a Zetasizer Nano Series (Malvern Instruments Ltd., UK) according to the
manufacturer's protocol.

4.3.9

In vitro uptake of liposomes loaded with Cy3 siRNA (Folatelipo-Cy3 siRNA)

Freshly prepared mouse bone marrow cells (2x105) and B16-F10 cells ( 2x105/well) were
plated in 12 well/plate and transfected with Folate-lipo-Cy3 siRNA, Non-folate-lipo-Cy3
siRNA. Cells were harvested 4 h after transfection and Cy3 fluoresence were analyzed by
flow cytometry.

4.3.10

In vitro silencing of B-RAF in B16-F10 using Folate-liposiBRAF

B16-F10 cells were plated into 24-well plates (1.5×105 cells per well) and allowed to
grow overnight, to reach 80% confluence. Then cells were transfected with Folate-liposiBRAF or Folate-lipo-siScramble for 24 h. Total cellular RNA was isolated from B16F10 cells 24 h after transfection for qPCR analysis.
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4.3.11

In vivo distribution of Folate-lipo-Cy3-siRNA

C57/BL6 mice were used for melanoma inoculation using B16-F10 cells (2x105/ mice).
Mice bearing melanoma were ready to be used when tumors reached the size of 500mm3.
Non-folate-lipo-Cy3siRNA or Folate-lipo-Cy3 siRNA were injected intravenously into
mouse tail veins (50 μg/ mouse). Mice were euthanized 6 h post-injection and organs
(tumor, heart, liver, spleen, lung and kidney) were collected, rinsed with saline, snapfrozen in liquid nitrogen, mounted for cryostat sectioning, and viewed using fluorescence
microscopy.

4.3.12

In vivo silencing of BRAF using Folate-lipo-siBRAF

Folate-lipo-siBRAF and Non-folate-lipo-siBRAF were injected intravenously into mouse
tail veins (50 μg/ mouse). Mice were euthanized 24 h later and tumors were collected for
RNA isolation. All RNAs were prepared for qPCR analysis.

4.3.13

Quantitative PCR analysis of B-RAF mRNA

After in vivo treatment of mice or in vitro treatment of B16-F10 cells with liposomes
loaded with control or B-RAF siRNA, total cellular or tissue RNA was isolated using
Trizol (Invitrogen) and then used as a template for cDNA synthesis and quantitative PCR
(qPCR). qPCR reactions using gene-specific forward and reverse primers (100 nM each)
and SYBR Green PCR Master mix (Stratagene, La Jolla, CA,) in a Stratagene MX 4000
Multiplex qPCR System. Primers used for the amplification of murine B-RAF and
GAPDH were: B-RAF, 5’-CAATTGGCTGGGACACGGACAT-3’ (forward) and 5’TTGACAACGGAAACCCTGGAAAAG-3’(reverse); GAPDH, 5’TGATGACATCAAGAAGGTGGTGAA-3’ (forward) and 5’ TGGGATGGAAATTGTGAGGGAGAT-3’ (reverse).

146

4.3.14

Effect of Folate-lipo-siBRAF on in vivo mouse melanoma
tumor growth

B16-F10 mouse melanoma cells (2 x 105 cells) were suspended in 20 μl of PBS and
injected s.c. and dorsally into each C57BL/6 mouse. Folate-lipo-siIDO or control
liposomes encapsulates 100 g siRNA in a volume of 300 l were injected i.v. into mice
2 days after injection with tumor cells and once per week thereafter. Control mice were
identically injected with tumor cells followed, at the same time as injection of mice with
Folate-lipo-siIDO, Folate-lipo-siScrambled, or non-folate-lipo-siIDO were also injected.
Mice were checked for tumor formation on alternate days. Each tumor was measured by
caliper and volumes estimated using the following formula: tumor volume = 0.5 x
(width2) x (length).Mice were sacrificed 21 days after tumor inoculation and tumor was
extracted for weighting.

4.3.15

Immunohistochemistry staining of PCNA and Isolectin B4 in
tumor tissue

The melanoma tissue was fixed in 4% paraformaldehyde. Sections were incubated with
primary antibody of antiPCNA and Griffonia Simplicifolia Lectin I (GSL I) – Isolectin
B4 (IB4) (Vector, Burlington, Ontario, CA) mAb at 1:100 dilution. Then the sections
were incubated with biotinylation secondary antibody for 45 min, followed by
horseradish peroxidase-labeled streptoavidin at 37◦C for 45 min. Slices were finally
developed with diaminobenzidene (DAB) and counterstained with hematoxylin. Slices
were observed under microscopy in a magnification of 400x. Tunel staining was using
TdT FragEL TM DNA Fragment Detect Kit (Billerica, MA, USA). Slices were observed
under microscopy in a magnification of 200x.

4.3.16

Statistical analysis

Data are presented as means ± SEM. Control and experimental data were compared using
one-way ANOVA followed by Newman-Keuls testing. P-values less than 0.5 were
assumed a priori to indicate significant differences.

147

4.4

4.4.1

Results

In vitro silencing and anti-proliferation assay on B16-F10
cells by B-RAF siRNA

B-RAF is an important cascade kinase in the classical MAPK pathway, which plays a
crucial role in cell proliferation and survival. The mutation induced overexpression of BRAF and stimulates proliferation and survival, thus providing essential tumor growth and
maintenance functions [24].Suppression of B-RAF mutations using chemical inhibitors
are known to restrict tumor cell growth[25, 26]. In this study, we proposed to knock
down B-RAF using siRNA, which could be more specific, fewer potential side effects
and potent [27-30]. In order to detect the silencing efficacy and the inhibition ability of
the B-RAF siRNA, in vitro siRNA transfection was applied on B16-F10 cells. siBRAF
and siScramblewas were transfected in to B16-F10 cells and the B-RAF mRNA and
protein expression levels were detected by qPCR and western blot respectively (Fig. 4-1,
A and B). Based on the result, the mRNA expression level of B-RAF was knocked down
by more than 80% (Fig. 4-1A) and the protein expression is also largely reduced in the
siBRAF treated cells (Fig. 4-1.B). It demonstrates that the siBRAF could efficiently
repress the B-RAF expression level in B16-F10 cells.
To evaluate the inhibition efficacy of cell growth by siBRAF, a cell proliferation assay
was used. After siBRAF and siScramble transfection, cells were subcultured and
harvested at indicated time points, proliferation rate was determined by MTT assay and
Trypan blue assay (Fig 4-1, C and D). According to the result, cell proliferation rate
decreased up to 65% in 96 h (Fig. 4-1C) and the proliferation rate started to decrease 48 h
after
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Figure 4-1 In vitro gene silencing and anti-proliferation assay on B16-F10 cells by BRAF siRNA. (A&B) Determination of the silencing efficiency of B-RAF siRNA.
siBRAF and control siScrambled were transfected by lipofectamine 2000 into B16-F10
cells. (A) 24 h post transfection, cells were harvested and the total mRNA were isolated.
The B-RAF expression level was determined by qPCR. (B) 72 h post transfection, cells
were harvested and the B-RAF protein expression level was determined by western blot.
(C&D) Determination of the anti-proliferation effect of B-RAF siRNA on B16-F10 cell.
siBRAF and control siScrambled were transfected into B16-F10 cells by lipofectamine
2000. (C) 92 h after transfection, MTT assay was conducted as described in Materials and
Methods. 4 h post addition of MTT, absorbance was detected by microreader. (D) After
transfection, cells were relocated from 12well plate into 96 well plate in a number of
1000/well. Cells were harvested, stained with trypan blue and cell numbers were counted
under microscope in 24 h, 48 h, 96 h and 120 h post transfection.
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transfection. Thereafter, the difference between siScamble control and Non treatment
control increased continually till 120 h, which implies that the silencing effect could be
maintained within siBRAF transfected cells for at least 120 h (Fig. 4-1D).

4.4.2

Characterization of Folate-lipo-siRNA

Size and surface charge of liposomal nanopartticles are important for in vivo delivery
particles, since larger size particle might ends up eaten by Kupffer and other
reticuloendothelial cells rich organs, while negatively charged particles are repelled by
siRNA and cell plasma membrane components [1, 18, 31]. To estimate the size and
surface charge of the Folate-lipo-siBRAF, the diameter and the zeta potential (represents
the surface charge) was detected (Fig. 4-2 A and B). Based on the result, the diameter of
the folate-lipo-siBRAF was around 160nm (Fig. 4-2A) and the zeta potential is around 37
mV (Fig. 4-2B). According to the previous report [32], the size and the surface charge of
the prepared liposomes were suitable for potential in vivo siRNA delivery.
The rapid degradation of siRNA is another major hurdle of siRNA in vivo delivery [33,
34]. To determine whether siRBAF were encapsulated and protected by the Folate
liposomest, a degradation assay was applied using 90% FBS mixing with folate-liposiBRAF, Non-folate-siBRAF or naked siBRAF. Compare to the naked siBRAF, Folatelipo-siBRAF and Non-folate-siBRAF could protect siBRAF from being degraded at least
48 h (Fig. 4-2 C), which implies that both the Folate and Non-folate liposome provide
protection against systemic degradation of siRNA by nucleophiles and nucleolytic
enzymes, and that addition of folate to liposomes does not influence the protective
capacity.

4.4.3

In vitro targeting assay of Folate-lipo-Cy3-siRNA and gene
silencing of B-RAF

FRs are known to express in many malignant tumor cells but not normal cells [18]. To
determine the preferentially targeting efficacy of the Folate-lipo-siRNA towards
malignant cells, an in vitro cell targeting assay was applied. Freshly cultured bone
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Figure 4-2 Preparation and characterization of Folate-lipo-siRNA. (A & B)
Determination of the size and zeta potential of Folate-lipo-siRNA.Folate-lipo-siRNA and
non-folate-lipo-siRNA were prepare as described in the Materials and Methods. The size
(A) and the zeta potencial (B) of Folate-lipo-siRNA and non-folate-lipo-siRNA were
measured by zetasizer. (C) Serum protection assay. Naked siRNA, Folate-lipo-siRNA, or
non-folate-lipo-siRNA were incubated with 90% FBS at 37 oC at various time points. 1, 4,
8, 24 and 48 h post incubation, liposomes that encapsulated siRNA were harvested by
Trizol, siRNA was isolated by chloroform and isopropanol method, then visualized by
15% page gel electrophoresis. The data presented one of three independent experiments.
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marrow cells (non-FR-expressing controls) and consistently FR-expressing B16-F10 cells
were transfected with both Folate-lipo-Cy3-siRNA and Non-folate-Cy3-siRNA.The
intensity of the Cy3 fluorescent in cells were detected by Flow cytometry (Fig. 4-3 A).
From the result, we observed much higher uptake of Folate-lipo-Cy3-siRNA in tumor
cell B16-F10 when compare to normal bone marrow cells, while similar uptake of Nontargeting-Cy3-siRNA was observed in both cells. While there are large differences
between Folate-lipo-Cy3-siRNA and Non-folate-Cy3-siRNA in FRs expressing cells, the
difference is trivial in non FRs expressing cells. It illustrated that, most of the uptake of
Folate-lipo-Cy3-siRNA were FRs expression associated. While the characteristics of the
Folate-lipo-Cy3-siRNA and the Non-folate-lipo-Cy3-siRNA do not influence much of
the transfection rate, the addition of folate to liposomes makes large difference in targeted
delivery capability.
To evaluate the in vitro silencing ability of Folate-lipo-siBRAF, B16 cells were used and
transfected with Folate-lipo-siScramble and Folate-lipo-siBRAF respectively. 24 h later,
cells were harvested and the BRAF expression was determined by qPCR. Compared to
Folate-lipo-siScramble treatment group, BRAF expression in cells treated with Folatelipo-siBRAF was significantly knocked down to 70% (Fig. 4-3B), which demonstrates
that Folate-lipo-siBRAF is potent for in vitro silencing.

4.4.4

Bio-distribution of Folate-lipo-Cy3-siRNA and in vivo gene
silencing of B-RAF

Cell surface receptors for folic acid are generally overexpressed in human cancer cells
[35]. In mouse melanoma, B16-F10 consistently expresses FRs. To determine the in vivo
targeting efficacy of Folat-lipo-siBRAF, melanoma bearing mice were used for the in
vivo targeting assay. Mice inoculated with B16-F10 melanoma and bearing melanoma
tumors were intravenously injected with Folate-lipo-Cy3-siBRAF or Non-lipo-Cy3siBRAF. Based on the intensity of the fluorescent, an overall stronger fluorescent in
tumor tissues that administrated with Folate-lipo-Cy3-siBRAF than the tumor tissues that
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Figure 4-3 In vitro targeting assay of Folate-lipo-Cy3-siRNA and gene silencing of
BRAF. (A) Transfecting efficacy of Folate-lipo-Cy3-siRNA detected by flow cytometry.
B16-F10 cells and freshly prepared bone marrow cells were transfected by Folate-lipoCy3-siRNA and non-folate-lipo-Cy3-siRNA. 4 h after transfection, the cells were
harvested and the fluorescence of encapsulated Cy3-labeled siRNA was detected by flow
cytometry. (B) Gene silencing of BRAF using Folate-lipo-siBRAF. B16-F10 cells were
transfected by Folate-lipo-siBRAF and Folate-lipo-siScramble. 24 h after transfection,
cells were harvested and the mRNA were isolated. The BRAF expression of B16-F10
was detected by qPCR. **p<0.01
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administrated with Non-lipo-Cy3-siBRAF can be observed. Strong fluorescence was
observed in liver while little was seen in spleen. No fluorescence was detectable in other
vital organs. Moerover, the fluorescence in tumor tissues are more collective than those
in liver and spleen, which might attribute to the disorganized vascularization in tumor
tissue (Fig. 4-4A). Although the strongest fluorescence can be observed in liver, strong
fluorescence could be seen in tumor tissue in Folate-lipo-Cy3-siBRAF administrated
mice. Remarkably, the flourecence in tumor tissue of the Folate-lipo-Cy3-siBRAF
administrated mice is much stronger than the tumor tissue of Non-lipo-Cy3-siBRAF
administrated mice, which illustrated that Folate-lipo-siBRAF is able to enhance the
delivery of the siRNA into tumor tissue and the addition of folate to the liposomes could
increase the tumor delivery efficacy.
For efficient drug delivery, a carrier system should facilitate not only tumor localization
but also intracellular access [35]. To estimate the ability of the Folate-lipo-siBRAF in
helping the encapsulated siRNA reaching the targeted cells and therefore induce silencing
of the intended gene, in vivo tumor silencing assay was applied. Folate-lipo-siBRAF and
Folate-lipo-siScramble were intravenously injected into melanoma bearing mice. 24 h
post administration, mice were sacrificed and tumor tissues were extracted for qPCR.
Based on the qPCR result, the BRAF mRNA expression level has been largely knocked
down when compare to Non treatment control and scramble control (Fig. 4-4B), which
proves that Folate-lipo-siBRAF is capable in repressing the BRAF expression level in
vivo in tumor tissue.

4.4.5

Anti-tumor growth of melanoma by Folate-lipo-siBRAF.

The inhibition of B-RAF in B-RAF overexpressing malignant cells would restrict the
growth of the tumor [26]. To determinate whether the Folate-lipo-siBRAF is able to
restrict tumor growth in vivo, Folate-lipo-siBRAF was applied as a therapy for melanoma
bearing mice. Folate-lipo-siBRAF, Non-folate-lipo-siBRAF and Folate-lipo-siScramble
was intravenously injected to the tumor bearing mice two days after tumor inoculation
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Figure 4-4 Bio-distribution of Folate-lipo-Cy3-siRNA and in vivo gene silencing of BRAF. (A) Bio-distribution of Folate-lipo-siRNA. Mice were i.v injected with Folate-lipoCy3-siRNA and non-folate-lipo-Cy3-siRNA. 6 h post administration, mice were
sacrificed and tumor tissues, liver, spleen, lung, kidney and heart were extracted for
frozen section. The red fluorescence of Cy3-labeled siRNA in the various tissue sections
were observed under a fluorescent microscope. The data presented one of three
independent experiments. The magnification was 10x. (B) In vivo gene silencing by
Folate-lipo-siBRAF. Folate-lipo-siBRAF or Folate-lipo-siScrambled were i.v injected
into C57/BL6 mice. 24 h after injection, mice were sacrificed and the B-RAF expression
in tumor tissue was detected by qPCR. **p<0.01.
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and once/week thereafter. Base on the tumor size measurement data, mice treated with
Folate-lipo-siBRAF have significantly smaller tumor size in the same day after tumor
inoculation when compare to Non treatment control, Non-folate-lipo-siBRAF and Folatelipo-siScramble (Fig. 4-5 A). Mice treated with Non-folate-siBRAF also had a relatively
smaller tumor size when compare to Non treatment control and Folate-lipo-siScramble,
however, the difference was not significant.
21 d after tumor inoculation, mice were sacrificed and tumors were extracted for weight
evaluation. Mice in Folate-lipo-siBRAF treatment groups have significantly small tumor
weight as comparing to Non treatment control, Non-folate-lipo-siBRAF and Folate-liposiScramble treatment groups (Fig. 4-5 B). It demonstrated that Folate-lipo-siBRAF is
able to restrict tumor growth and the therapeutic effect is much better when there folate is
added into the delivery system.

4.4.6

Anti-proliferation, anti-vascularization in melanoma by
Folate-lipo-siBRAF

The inhibition of B-RAF would induce less proliferation and more apoptosis, which
serves as the major drive of tumor growth restriction [29]. Proliferating cell nuclear
antigen (PCNA) was identified as the processivity factor of DNA polymerase delta
(PFDPδ) [36, 37], which is part of a donut-shaped multi-protein complex playing a role
in DNA repair and replication [38, 39]. It is a well-conserved protein in all eukaryotic
species which is a processivity factor of DNA polymerased that required for DNA
synthesis [40-43]. To determine whether Folate-lipo-siBRAF treated tumor tissue were
restricted in proliferation, immunochemistry staining was applied. Based on the result,
Folate-lipo-siBRAF treated tumor tissue has much less PCNA (Fig. 4-6 A) expression
than Non treatment control, Non-folate-lipo-siBRAF and Folate-lipo-siScramble
treatment groups, which illustrates that the Folate-lipo-siBRAF is able to induce in vivo
anti-proliferation in tumor, and therefore restrict tumor growth. There is trivial difference
between the Non treatment control, Non-folate-lipo-siBRAF and Folate-lipo-siScramble
treatment groups, which implies that although the fluorescence in tumors can be seen in
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Figure 4-5 Anti-tumor effects of Folate-lipo-siBRAF. (A & B) Experimental treatment of
murine melanoma using Folate-lipo-siBRAF. Folate-lipo-siBRAF, or non-folate-liposiBRAF, or Folate-lipo-siScramble was i.v. injected into C57/BL6 mice two days after
tumor inoculation. Treatments were repeated once a week thereafter. Tumor size (A).
Tumors in treatment and control mice were monitored every three days. Tumor weight
(B). Tumours in different experimental groups or control groups were extracted and
weighted in day 21 after mice were sacrificed. Each point represents the weight of 6 mice
in each group. Results represent 1 of 3 experiments. **p<0.05.
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Figure 4-6 Anti-proliferation effects by Folate-lipo-siBRAF in melanoma. Immune
histochemistry staining of PCNA in tumor tissues. 21 days after tumor inoculation, mice
in different experimental groups were sacrificed and the tumor tissues were harvested for
immune histopathology staining. (A) PCNA positive cells in Non-treatment, Folate-liposiBRAF, non-folate-lipo-siBRAF, or Folate-lipo-siScramble treated tumor tissue were
displayed.
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Non-folate-lipo-siBRAF, the uptake of the liposome is not efficient enough to restrict the
tumor growth. Lectins are specific carbohydrate-binding proteins that have been applied
in identifying the glycosylation status specifically in a variety of tissues [44-46]. Within
the lectins family, IB4 has been shown to be useful for analysis of microvascular
structure and function. IB4 binds on various cells that express α-galactosyl residues,
including endothelial cells [45-48] in normal mouse, rabbit, rat and human tissues [49].
IB4 also has been used to identified neovascular structures specifically within tumor
vascular networks [50]. To determine whether Folate-lipo-siBRAF treated tumor tissue
were restricted in vascular network or not, IB4 was used to stain the melanoma tissues in
various experimental groups (Fig. 4-7B). According to the result, mice treated with
Folate-lipo-siBRAF have much less microvasculature than the Non treatment control,
Folate-lipo-siScramble and Non-folate-lipo-siBRAF treatment group, which implies that
the in vivo silencing of BRAF is able to restrict the vascular network. Although the
melanoma tissues treated with Non-folate-lipo-siBRAF have slightly less endothelial
cells, the difference between the Non treatment group and Folate-lipo-siScramble control
group is trivial, which illustrates that with the folate ligand, the liposomal system
provides better therapeutic effect.

4.5

Disscussion

Melanocytes originate from highly motile cells with enhanced survival properties, which
attribute to the high aggressiveness, high metastasis and high resistance to cytotoxic
agents. When compare to other malignancies, melanoma is more resistance to
chemotherapy, radiotherapy and immunotherapy, which is a major barrier for successful
treatment [52]. Targeted therapies that focus on those which cancer cells have come to
depend for progression are most attractive[53]. B-RAF is implicated in several aspects of
melanoma induction and progression. Several years after B-RAF mutation was
discovered, the first selective inhibitors, vemurafenib, has entered clinical trials. However,
after the regression in the early course of the therapy was recorded, it is observed that
resistance to therapy emerged in the subsequent and follow-up treatment. The response
duration ranged from 2 to >18 months. Now, a lot of research groups have focus on the
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Figure 4-7 Anti-vascularization effects by Folate-lipo-siBRAF in melanoma. (B)
Immuno histochemistry staining of IB4. 21 days after tumor inoculation, mice in different
experimental groups were sacrificed and the tumor tissues were harvested for immuno
histopathology staining. IB4 positive endothelial cells in Non-treatment, Folate-liposiBRAF, non-folate-lipo-siBRAF, or Folate-lipo-siScramble treated tumor tissue were
displayed.
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resistance mechanism in B-RAF therapy [53]. siRNA could be an alternative choice: it is
potent, highly specific to the targeting mRNA sequence and less toxic or size effect.
Moreover, siRNA has more potential in controlling more than one gene’s expression,
which offers great potential for “personal” cancer therapy [54]. In our study, we observe
a potent silencing of B-RAF expression by siRNA and a significantly decrease of cell
proliferation in vitro and tumor growth in vivo.
However, in vivo application of siRNA faces many challenges. First, siRNA is not stable
in circulation. Second, to achieve effective in vivo RNAi application, tissue barrier and
intracellular delivery have to be overcome. Third, cell entrance and endsomal escape are
the crucial issues for siRNA delivery. Fourth, siRNA in tumor delivery is especially
difficult since tumor vasculature is poorly organized, tortuous, defective and locationdependent heterogeneity. Therefore, when compare to normal tissue, tumors have lower
blood flow, higher flow resistance and as a result, lower presentation of siRNA to tumors.
Meanwhile, tumor blood vessels have discontinuous endothelium, which makes it leaky
and permeable to larger size molecules (100 – 780nm). These properties facilitate larger
siRNA combined nanoparticles (e.g., 100nm) extravasation through diffusion and
convection in tumors and realize passive tumor targeting [55-59]. Thus, an effective
delivery system is needed.
Folate based targeting systems already be successfully applied as a therapeutic agents or
imaging agents[60, 61]. Comparing liposomes with other carrier delivery systems,
liposomes offer multiple advantages for drug delivery, including their biocompatibility,
biodegradability and safety. Further, liposomes are able to accumulate within tumor
tissue due to the passive accumulation of colloidal macromolecules of approximately
40kDa and above in tumors, which cause the enhanced permeation and retention effect
(EPR) [62]. The accumulation of liposomes in tumor tissue could be improved through
the use of receptor targeting moieties that are either postconjugated to the surface of
liposomes or attached to lipids that become incorporated within the liposomal bilayer[31].
Since FRs are generally overexpressed on human cancer cells [21, 43, 63, 64] and the
affinity of FRs will not be affected when PEG covalently connected the -carboxyl [20,
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65] of folate. Therefore, liposomes that included folate conjugated lipids have been
considered as promising non-live vectors for tumor targeted delivery purposes.
In our study, we observed a protective effect of the folate liposome to the encapsulated
siRNA and a significantly preferential targeting effect in Folat-lipo-siBRAF, which offer
a promising delivery system for siRNA tumor delivery.
However, excessive cationic charge would induced the the first-pass clearance by lung
and liver, which offer strong reticuloendothelial system (RES) that allows strong
interaction between the cationic surface of the liposome-siRNA complex (lipoplex) and
the plasma proteins [2, 3, 66]. In our study, we observed an intense fluorescence in liver,
however, no fluorescence in lung. What’s more, a relative strong fluorescence could be
seen in tumors, which implies that the liposome we generated is not too “cationic” that
enable it better escaping the RES and further being delivery into tumor. One of the
methods to shield the charge of lipoplexes is to add additional neutral membrane bilayer
outside the lipoplex[40, 67]. In the same purpose, in our procedure of generating the
lipoplex, we added DSPE-PEG lipids, which is a neutral lipids, after extrusion and before
it could be used. In fact, the in vivo study results show that the liposome was able to
deliver siBRAF into B16-F10 melanoma and silenced the B-RAF expression in tumor,
with the silencing efficacy potent enough to restrict the tumor growth.
Human v600E B-RAF, which is a mutation of B-RAF that leads to the overexpressiong of
B-RAF, stimulates constitutive ERK signalling, stimulating proliferation and survival and
providing essential tumour growth and maintenance functions [68]. v600EBRAF also
contributes to neoangiogenesis by stimulating autocrine vascular endothelial growth
factor (VEGF) secretion. It has been shown that, the blockade of RAF/MEK/ERK
pathway could induce apoptosis, especially in B-RAF V600E melanoma cells [69-71].
Apoptosis is a frequent sign of the response to B-RAF inhibitor, such as
PLX4032/RG7204, an analogue to PLX4720, which suggesting that it is the major
biological consequence of inhibition of mutant B-RAF [51]. Based on the immunehistopathology staining, we observed a similar anti-tumor effect with human that by
reducing the BRAF expression in tumor cells, the proliferation of the tumor cells as
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decreased and less endothelial cells were observed, which implies the anti-proliferation
effects, anti-vascularization and increase apoptosis effects of the Folate-lipo-siBRAF.
In summary, we report here a folate receptor expressing malignant cells targeting systems
to delivery B-RAF siRNA can efficiently block the B-RAF expression in tumor cells in
vitro and tumor tissues in vivo. Treatment of Folate-lipo-siBRAF results in significantly
reduced tumor size and tumor weight; decreased tumor cells proliferation, reduced tumor
tissue capillary and increase tumor cells apoptosis in vivo.
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Chapter 5

5

General Discussion

5.1 General Discussion
The studies throughout this thesis focus on examining the validation of different RNAi
therapies for different diseases. To study the validation of RNAi as a potential therapy,
two disease models and four specific siRNA sequences were applied in Chapters 2-4. In
each chapter, a specific RNAi therapy was examined:
 Validation of transdermal delivery by a novel topical delivery reagent of siTNFα
and siMyD88 in contact hypersensitivity therapy.
 Determination of whether mannosed liposomes encapsulating siIDO is a good
immune therapy for melanoma.
 Determination of whether folated liposomes encapsulating siBRAF is a good
therapy for melanoma.
In Chapter 2, we describe development of a topical delivery reagent for efficient delivery
of siRNA into dermis as a potential therapy for ACD. The current standard for ACD
treatment involves local application of corticosteroids that target lymphocyte activation.
However, this method results in many unwanted side effects. These side effects can
become amplified when addiction to cutaneous application requires increasing dosages.
We propose that topical application of siRNA could alleviate some of these problems
since it directly contacts the disease site, restricts toxicity to the application area, and is
user-friendly. However, as previously discussed, effective topical siRNA delivery
requires penetration-enhancing techniques to infiltrate the SC and reach target cells.
There are two routes of passive diffusion for permeation of the SC: the trans-epidermal
route and the trans-appendageal route. The trans-epidermal route can be further broken
down into two pathways: polar or hydrophilic compounds prefer passing through the
stacked layers of corneocytes, while lipophilic compounds favour travelling through the
intercellular spaces [1, 2]. Although the intercellular space route only occupies 1% of the
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available area [3], it is thought to be the predominant route of entry through the stratum
corneum [4]. In 1997, Menon and Elias suggested the “aqueous pore pathway” [5], which
states that the discontinuous lacunar domains in the lipid matrix will expand and become
a continuous pathway when the SC is being hydrated. With the removal of the
permeabilizing agent, the continuous lacunar domains will recover to a fragmented state
[6].
The trans-appendageal penetration route is through skin appendages such as sweat glands,
sebaceous glands, and hair follicles. However, these pathways only occupy a small area
of the total cutaneous surface, so they play a limited role in drug diffusion [7, 8]. Of the
possible appendages in skin, the hair follicle is likely to play the largest role due to its
relatively large size, and the presence of sebum in the duct of the pilosebaceous gland
could facilitate the diffusion of lipophilic drugs [3]. Many studies using various methods,
such as confocal laser scanning microscopy, biopsies, and tape stripping techniques have
been used to study the penetration of drug molecules through the hair follicles [7]. Under
the stratum corneum are the layers of the epidermis, which is 50-100 μm in thickness in
total. These layers contain live, nucleated cells that have much less resistance to diffusing
compounds [3]. Extremely hydrophilic or lipophilic molecules might have difficulty in
penetrating this portion of the epidermis since the cells form tight linkages, limiting
diffusion through the cell membranes and cytosol [9]. Based on the data in Chapter 2, it is
possible that the novel topical reagent penetrates the SC via both trans-epidermal and
trans-appendageal routes. Under the fluorescent microscope, fluorescence could be seen
distributed evenly throughout both the SC layer and other layers of cells in the dermis,
which implicates the trans-epidermal route. Stronger fluorescence could also be seen in
hair follicles illustrating the trans-appendageal route. By utilizing both routes, the novel
reagent could reach higher transdermal ability. The topical reagent is neither too
hydrophilic nor lipophilic, which facilitates its penetration through the living cell layers
of the dermis. Helping siRNA penetrate the living cells of the dermis, including
Langerhans cells in the stratum spinosum, could alter their biologic function through
silencing.
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Tumor necrosis factor (TNF) is a systemic inflammation-induced cytokine and a member
of a group of cytokines that stimulate the acute phase reaction. It can be produced by
CD4+ lymphocytes and NK cells, but is mainly produced by activated macrophages (M1).
The primary role of TNF is in regulating immune cells. It can induce fever, apoptotic cell
death, sepsis (by inducing IL1 and IL6 production), cachexia, inflammation, and it can
inhibit tumorigenesis and viral replication. TNFα is one member of the TNF family of
receptor ligands. It has multiple biological activities, including immunomodulation and
oncostatic, osteolytic, pirogenic, proinflammatory, and other activities [10].
The first TLR adaptor molecule discovered was MyD88. It is induced by IL-6 and was
isolated from M1 myeloleukaemic cells differentiated into macrophages by IL-6
treatment, and characterized as a myeloid differentiation response gene [9]. MyD88 is a
TIR domain-containing cytoplasmic protein. The pathway activated by the TIR domain
of TLRs that recruits MyD88 has been widely studied [11]. With the exception of TLR3,
MyD88 mediates signaling by all TLRs [1]. MyD88 interacts with IL-1 receptor
associated kinase 4 (IRAK-4), causing IRAK-4 and IRAK-1 to form a complex which
leads to its phosphorylation and activation [2]. IRAK-4 and IRAK-1 then dissociate from
the complex and interact with tumour necrosis factor (TNF) receptor-associated factor-6
(TRAF-6), which then recruits transforming growth factor-activated kinase-1 (TAK-1)binding protein-1 (TAB-1) and TAB-2 to the complex. This leads to the phosphorylation
and activation of the kinase TAK-1 [4]. Next, TAK-1 activates kinases upstream of p38
and JNK and the inhibitory κB (IκB) kinase (IKK) complex leading to NF-κB activation
[3].
Once established, ACD is a lifelong disease. Prevention and avoidance of the causative
agent (hapten) is critically important. Prevention and avoidance are of even greater
importance for patients exposed to more than one sensitizer or extremely diffuse
sensitizers. Methods that limit hapten penetration may help to reduce hapten-peptide
complex formation, thus limiting the allergic reaction. However, the efficacy of these
methods is limited. Most of the therapeutic approaches against ACD aim at blocking T
cell transmigration to skin, reducing leukocyte activation, or preventing keratinocytedependent amplification of the inflammatory response.
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With understanding of the mechanisms that govern T cell recruitment, many compounds
that could inhibit the leukocyte-endothelial cell interactions have been developed and
implemented in clinical trials. This approach has advantages in selectively targeting T
cell subpopulations while maintaining immunoprotection in other situations. However, it
is limited by the redundancy of the mechanisms involved in T cell extravasation and
positioning into the skin.
Other proposed targets in treatment of ACD include selectins (which mediate initial
rolling of leukocytes over the endothelium), adhesion molecules, and chemokinechemokine receptor pairs [12-14]. However, strategies that interfere either with selectin
functions or the modulation of the post-trascriptional glycosylation of selectin ligands
have all had disappointing results when tested in humans [15].
Another attractive strategy is to target chemokine receptors in selective leukocyte
subpopulations. Unfortunately, approaches to block chemokine-receptor axes have
provided inconsistent results [16].
Most of the therapies for ACD are currently based on systemically or locally
administrated drugs that target lymphocyte activation. Topical application of
corticosteorids remains the mainstay treatment of ACD. More severe ACD reactions
often require a systemic immunosuppressive treatment, typically based on a systemic
corticosteroid regimen or cyclosporine administration. Therapeutic effectiveness of
cyclosporine in ACD results from its dramatic effects on T cell functions, as well as on
cytokine release [6].
My study focuses on one of the most important cytokines in ACD (TNFα) as well as a
vitally important molecule in mediating transduction of innate immune signaling
(MyD88). In accord with reported data [7, 8], my study shows that a single treatment of
TNFα alone is not sufficiently potent to alleviate symptoms of ACD, with the exception
of a reduction in swelling.
In Chapters 3 and 4, I discuss two potential RNAi immune therapy for cutaneous
melanoma. Melanoma is the most deadly form of skin cancer. If diagnosed early,
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melanoma can be cured by surgical resection and approximately 80% of cases are dealt
with in this manner. Nevertheless, the metastatic nature of melanoma malignancies
results in high resistance to therapy and poor prognosis. Malignant melanoma patients
with metastatic disease have a median survival of 6 months and a 5 year survival of less
than 5%, illustrating the pressing need for new and better treatment.
Many factors could contribute to melanocyte oncogenesis, including mutations in critical
growth regulatory genes, the production of autocrine growth factors, and the loss of
adhesion receptors [12]. As melanocytes progress toward malignancy they proliferate and
spread, forming a naevus or common mole. The proliferation of melanocytes can be
restricted to the epidermis (junctional naevus), dermis (dermal naevus), or overlapping
components of both (compound naevus). Naevi are benign but have the potential to
progress to radial-growth-phase (RGP) of melanoma, which is an intra-epidermal lesion
that can involve some local micro-invasion of the dermis. RGP cells can further progress
into vertical-growth-phase (VGP), which is a more dangerous stage where cells tend to be
more invasive and metastatic and have nodules or nests of cells invading the dermis.
Melanocytes or naevi can directly develop to RGP or VGP, and cells in RGP or VGP can
progress into metastatic malignant melanoma.
There are four main clinical subtypes of melanoma [12]. Nodular melanoma consists of
raised nodules without a significant flat portion. Acral lentiginous melanoma (ALM) is
not associated with UV exposure since it is usually found on the palms of the hands, soles
of the feet, and in the bed of fingernails or toenails. In non-Caucasian populations, ALM
accounts for 50% of melanomas [13]. Lentigo maligna tends to correlate with chronic sun
exposure since it occurs in the elderly on sun-exposed skin regions. It is generally flat in
appearance. Superficial spreading melanoma (SSM) is the most common form of
melanoma. It linked to severe sunburn, especially at an early age. It is usually flat with an
intra-epidermal component. SSM accounts for the remaining 50% of melanomas in nonCaucasians. It is the third most common cancer in young people in the UK and USA [14,
15].
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Melanoma is recognized as an immuno-responsive type of tumour since T lymphocyte
infiltration into the tumour correlates with improved patient survival [17]. A longstanding
conventional therapy for melanoma involves administration of interleuklin-2 (IL-2). IL-2
is thought to exert antitumour effects by enhancing the host’s antitumour response and by
inducing T cell activation. IL-2 treatment alone results in a response in only
approximately 15% of cases. Moreover, the use of IL-2 in high doses is associated with
considerable mortality, attributed to the development of gastrointestinal, cardiovascular,
renal and neurological toxicities including vascular leakage syndrome where fluid
accumulates within the lung and liver. Another therapeutic approach is to use type I
interferons (IFN-α, IFN-α2). In some studies, IFN-α and IFN-α2 treatment has proven
beneficial in prolonging disease-free survival when applied in an adjuvant setting. A
modified IFN-α2 treatmment has entered a phase III study where its use as a single
agent versus combination with other treatments in an adjuvant approach [18].
In spite of the demonstrated capacity of the immune system to mount an antitumour
attack, tumours are still able to evade that attack, a process known as immune escape.
IDO is one important factor aiding escape of tumours from immune attack. In Chapter 3,
I described application of man-lipo-IDO, which targets a broad range of mannose
receptor-expressing APCs, to silence IDO expression in those APCs to achieve a
therapeutic effect. This preferential targeting strategy has both advantages and
disadvantages. One disadvantage is the case of non-specific binding to non-mannosereceptor-expressing cells and tissues: this increases the required dose of siRNA to be
delivered due to intended cells and tissues, where silencing of the unintended gene would
prove inconsequential or, perhaps, deleterious. However, an advantage of targeting not
only DCs but all mannose receptor expressing APCs is that it might offer broader
therapeutic effects that contribute more than expected. This notion stems from the fact
that DCs and IDO-expressing DCs represent only a very small subpopulation of immune
cells. Overall, a broader APC targeting approach could be more effective than extremely
specific targeting strategies.
Melanoma is an aggressive tumour that is resistant to all standard anticancer therapies.
Resistances mechanisms in melanoma are complex since a wide range of antineoplastic
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treatments are ineffective at killing melanoma cells. In this tumour type, it is suggested
that drug resistance is due to the inherent malignant behavior of melanoma cells rather
than acquired genetic alternations selected for over therapy [19]. The success of systemic
therapy for metastatic melanoma has been minimal [20]. The identification of mutant BRAF as a major driver of melanoma progression appeared as a breakthrough in
melanoma therapy [21]. The development of vemurafenib, a B-RAF kinase inhibitor with
high specificity for mutant B-RAF was a turning point [22, 23]. Vemurafenib progressed
rapidly through early phase trials and significant levels of tumor shrinkage were seen in
patients whose melanomas harbored B-RAF V600E mutations [24, 25]. The overall
response rate for vemurafenib was 48% compared with 5% for dacarbazine [26].
However, almost all patients treated eventually developed resistance and most tumours
progressed on therapy [25-27].
In Chapter 4, a lipid-based delivery system that targets oncogenic gene B-RAF was
applied as a strategy for treatment of melanoma. We found that using cationic lipid
delivering siRNA and preferentially targeting tumor cells is an effective way to treat
melanoma in the xenograft model we employed. It restricted tumor growth by inhibiting
tumor cell proliferation, reducing angiogenesis, and promoting tumour cell apoptosis. In
my study, however, there are still many areas that can be improved upon. First, it was
observed that the fate of most injected liposomes was the liver, and this accumulation of
therapeutic agent in non-target tissue remains a major barrier to improving the efficacy of
this therapy. Although most intravenously-administered drugs share this limitation, we
believe our system could be improved by further optimizing a novel combination of
lipids within the liposome or adjusting the ratio of already-used components. Second,
using a human xenograft model in immune-deficient mice could more realistically mimic
a clinical setting. Regardless of these limitations, we have established that RNAi therapy
could be a potential alternative for melanoma treatment.
Compared to other methods such as use of chemical inhibitors as therapeutic agents and
use of dominant-negative mutants to explore gene function, siRNA provides many
advantages. First, siRNA can be designed to target any class of genes (including both
protein-coding and non-coding RNAs) and can potentially silence the expression of any
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gene. Second, while constructing dominant negative mutants is time-consuming, siRNA
can be easily synthesized for direct administration or cloned into expression vectors for
expression in cultured cells in vitro or xenografts or induced tumours in vivo[28]. Third,
compared to both chemical inhibitors and dominant-negative mutants, siRNA-mediated
silencing is more specific and less toxic. Fourth, human tumours display different gene
expression profiles not only compared to normal tissue but also compared to each other.
Such heterogeneity would suggest the benefit of using a “personal” therapy approach.
The ability of detecting pathways that malignant tissue depends on and specifically
knocking them reveals the potential of RNAi to be a “personal” cancer therapy with
capacity to be specifically tailored to therapy of each individual patient, depending on the
molecular profile of their tumour [29, 30]. Finally, while most chemical inhibitors and
dominant-negative mutants are designed to inhibit only specifically-identified enzymatic
or other activities of over-expressed proteins in tumors (i.e., those attributable to specific
sub-regions of the protein, without affecting other, unidentified activities that could be
mediated by regions unaffected by targeted mutations or association with chemical
inhibitors), siRNA prevents production of the protein entirely, thus eliminating all
activities, both known and unknown. This makes RNAi a potent tool to inhibit function.
For the reasons outlined above, RNAi therapy is, overall, an attractive alternative to
knock down overexpressed genes involved in cancer progression and metastasis,
particularly where conventional treatment fails [31]. SiRNA has the potential to be more
effective than some current treatments of cancer because it targets the genetic material at
the core of the problem, while many other treatments aim only at reducing clinical
symptoms [32].
A major barrier to clinical application of siRNA is sub-optimal in vivo delivery. To
overcome this difficulty, many efforts have been exerted on developing a specific,
efficient and safe delivery method. At the same time, to validate it as a therapy, the
choice of target and the specific siRNA sequence itself are also vitally important.
Non-virus in vivo delivery strategies can be classified into two groups based on the route
of administration: local and systemic [33]. Local administration could be applied on
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easily accessible tissues. Local application of siRNA could directly deliver siRNA into
target tissues, which allows the accumulation of the proper siRNA amount and
substantially targeted release in the intended tissue. In our studies, we also used local
application of siRNA on skin for the treatment of ACD. Later on, we also discuss the
validation of using cationic lipids to achieve the systemic delivery of siRNA in treating of
melanoma [34].
Preformed cationic liposomes are among the most efficient in vitro transfection reagents
for nucleic acids/siRNA. The negatively charged phosphate backbone of siRNA can be
complexed electrostatically with cationic lipid, which contributes to its high efficacy [35,
36]. In addition, the net positive charge complexes can avidly bind to anionic
proteoglycans on cell surfaces, facilitating their uptake [36-38].
However, most of the commonly used cationic lipids have failed in clinical trials due to
poor in vivo performance because of excessive cationic charge, which results in low in
vivo transfection efficiency, toxicity, immune activation, and unfavorable biodistribution.
The lipoplexes are rapidly cleared when systemically administered because they
accumulate in the capillary bed of first-pass organs such as the lungs [39, 40]. After this
first clearance, hepatic elimination becomes the major factor for the lipoplexes 60
minutes after injection, just after the lipolexes redistribute from lung to liver [41]. In
many cases, lipoplexes would strongly interact with plasma proteins, leading to
entrapment and clearance by the RES system [42, 43]. Moreover, some studies found that
the siRNA lipoplexes could be easily dissociated in the presence of complete serum [44,
45].
In our study, all of the cationic liposomes generated by us contain polyethylene glycol
(PEG), which has been reported to be helpful in avoiding fast clearance and delaying
uptake of lipid-based nanoparticles into RES. PEG could shield and stabilize the lipid
bilayer as it is a hydrophilic polymer [46, 47]. However, the addition of negatively
charged PEG molecules could reduce liposome association with cell membranes, reduce
cell uptake, and reduce the potential for escape of siRNA from the endosomal
compartment (essential for antisense activity), thus lowering the overall transfection
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efficiency [46-48]. To address these issues, we further added a targeting ligand, which
aided the capacity of liposomes to be taken up into target cells through receptor-mediated
endocytosis. This led to significant increased in transfection efficiency for the targeting
liposome compared to our non-targeting liposomes.
In conclusion, the topical delivery reagent that delivers siTNFα and siMyD88 has the
potential for development into an effective RNAi therapy for ACD. The targeting
liposomes, Man-lipo-siIDO and Folate-lipo-siBRAF, could serve as potential antimelanoma RNAi therapies.
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